,INN_Name,BrandName,Phase,Applicants,LigID,pdbID,Type,RoF,MW,LogP,TPSA,HBA,HBD,NRB,Indications,Targets,Kinase_families,First_Approval,SC_Patent,Chirality,Synonyms,FDA_approved,Melting_points_C,Canonical_Smiles,InChIKey
0,Leniolisib,,0.0,Novartis,9NQ,['5o83'],,0,450.2,2.9,83.5,7,1,5,,,,,,Single Stereoisomer,"['CDZ173-NX', 'Leniolisib']",,,CCC(=O)N1CC[C@@H](C1)Nc2c3c(ncn2)CCN(C3)c4cc(c(nc4)OC)C(F)(F)F,MWKYMZXCGYXLPL-ZDUSSCGKSA-N
1,Nemiralisib,,0.0,GlaxosmithKline,VVX,['5ae8'],,0,440.2,4.9,77.0,5,2,5,,,,,,Single Stereoisomer,"['GSK2269557A', 'GSK-2269557', 'Nemiralisib']",,,CC(C)N1CCN(CC1)Cc2cnc(o2)c3cc(cc4c3cn[nH]4)c5cccc6c5cc[nH]6,MCIDWGZGWVSZMK-UHFFFAOYSA-N
2,Oclacitinib,,0.0,Pfizer,,,,0,337.2,1.5,91.0,5,2,5,,"['JAK1', 'JAK2', 'JAK3']",['Tyr'],,,Single Stereoisomer,"['Oclacitinib', 'JAKI', 'PF-03394197']",,,CNS(=O)(=O)C[C@H]1CC[C@@H](CC1)N(c2ncnc3c2cc[nH]3)C,HJWLJNBZVZDLAQ-HAQNSBGRSA-N
3,Toceranib,,0.0,Pfizer,,,,0,396.2,3.1,77.2,3,3,5,,['KIT'],['KIT'],,,Achiral Molecule,"['PHA-291639', 'Toceranib']",,,Cc1c([nH]c(c1C(=O)NCCN2CCCC2)C)/C=C\3/c4cc(ccc4NC3=O)F,SRSGVKWWVXWSJT-ATVHPVEESA-N
4,Dezapelisib,,0.0,Incyte Corporation,,,,0,421.1,3.7,100.9,8,2,4,,,,,,Single Stereoisomer,"['INCB040093', 'Dezapelisib']",,,Cc1csc2n1c(=O)c(c(n2)[C@H](C)Nc3c4c([nH]cn4)ncn3)c5cccc(c5)F,RSIWALKZYXPAGW-NSHDSACASA-N
5,Mavelertinib,,0.0,Pfizer,,,,0,415.2,0.7,115.0,10,2,6,,,,,,Single Stereoisomer,"['PF-06747775', 'Mavelertinib']",,,Cn1cc(c(n1)OC)Nc2c3c(nc(n2)N4C[C@H]([C@@H](C4)F)NC(=O)C=C)n(cn3)C,JYIUNVOCEFIUIU-GHMZBOCLSA-N
6,Selatinib,,1.0,Qilu Pharmaceutical,,,,2,564.1,6.5,89.3,7,2,11,,"['EGFR', 'ERBB2']",['Tyr'],,,,[],,,CS(=O)CCNCc1ccc(o1)c2ccc3c(c2)c(ncn3)Nc4ccc(c(c4)Cl)OCc5cccc(c5)F,OAMVGUFHZPRXOM-UHFFFAOYSA-N
7,Rivoceranib,,1.0,Advenchen Laboratories,,,,0,493.2,4.2,145.1,7,3,6,Rivoceranib Mesylate is a novel selective inhibitor of vascular endothelial growth factor receptor 2 (vegfr2),,,,,,['YN-968D1'],,,CS(=O)(=O)O.c1cc(c(nc1)NCc2ccncc2)C(=O)Nc3ccc(cc3)C4(CCCC4)C#N,FYJROXRIVQPKRY-UHFFFAOYSA-N
8,Panulisib,,1.0,Piramal Enterprises,,,,1,527.2,4.8,134.5,9,1,3,,"['PIK3CA', 'MTOR']",['Atypical'],,,Single Stereoisomer,[],,,CC(C)(C#N)c1ccc(cn1)n2c3c4cc(ccc4ncc3n(c2=NC#N)C)c5cc(c(nc5)N)C(F)(F)F,VJLRLTSXTLICIR-UHFFFAOYSA-N
9,Recilisib,['Ex-RAD'],1.0,Onconova Therapeutics,,,,0,336.0,3.6,71.4,3,1,5,,,,,,Achiral Molecule,"['Ex-RAD', 'ON-01210', 'ON-01210.Na', 'Recilisib']",,,c1cc(ccc1CS(=O)(=O)/C=C/c2ccc(cc2)C(=O)O)Cl,KBEKQQJUNVQLDZ-MDZDMXLPSA-N
10,Altiratinib,,1.0,Deciphera Pharmaceuticals,,,,1,510.2,5.0,109.4,5,3,8,,"['MET', 'TEK', 'KDR', 'NTRK1']",['Tyr'],,,Achiral Molecule,"['DCC-2701', 'Altiratinib', 'DP-5164']",,,c1cc(ccc1NC(=O)C2(CC2)C(=O)Nc3cc(c(cc3F)Oc4ccnc(c4)NC(=O)C5CC5)F)F,GNNDEPIMDAZHRQ-UHFFFAOYSA-N
11,Balamapimod,,1.0,Wyeth,,,,2,573.2,6.5,82.2,9,1,7,,"['RAF1', 'MAP2K1', 'MAP2K2']","['TKL', 'STE']",,,Achiral Molecule,"['MKI-833', 'Balamapimod']",,,Cn1ccnc1Sc2ccc(cc2Cl)Nc3c4cc(c(cc4ncc3C#N)N5CCC(CC5)N6CCCC6)OC,CVAKNHIXTWLGJO-UHFFFAOYSA-N
12,Lazertinib,,1.0,Genosco,,,,1,554.3,4.1,109.7,10,2,10,"Lazertinib (YH-25448, GNS-1480) is an inhibitor of the aberrant activity of EGFR mutant kinases, that was originally developed by Yuhan Corporation fo r antineoplastic potential in cancers with (acquired) resistance to existing EGFR tyrosine kinase inhibitors, in particular for EGFR mutation positive, advanced non-small cell lung cancer (NSCLC). In addition to predicted efficacy for the treatment of primary lung and extracranial lesions, lazertinib is expected to be beneficial for NSCLC brain metastases as it is able to cross the blood brain barrier.",,,,,,[],,,CN(C)Cc1cn(nc1c2ccccc2)c3ccnc(n3)Nc4cc(c(cc4OC)N5CCOCC5)NC(=O)C=C,RRMJMHOQSALEJJ-UHFFFAOYSA-N
13,Allitinib,,1.0,Allist Pharmaceuticals,,,,1,448.1,5.9,76.1,5,2,7,,"['ERBB2', 'EGFR']",['Tyr'],,,,"['AST-1306', 'ALL-3']",,,C=CC(=O)Nc1ccc2c(c1)c(ncn2)Nc3ccc(c(c3)Cl)OCc4cccc(c4)F,MVZGYPSXNDCANY-UHFFFAOYSA-N
14,Ravoxertinib,,1.0,Genentech,6QB,"['5k4i', '5k4j', '6oph']",,0,440.1,3.2,97.9,8,2,6,,,,,,Single Stereoisomer,"['Ravoxertinib', 'RG-7842', 'GDC-0994']",,,Cn1c(ccn1)Nc2nccc(n2)c3ccn(c(=O)c3)[C@H](CO)c4ccc(c(c4)F)Cl,RZUOCXOYPYGSKL-GOSISDBHSA-N
15,Pexmetinib,,1.0,Array BioPharma,,,,2,556.3,6.1,106.2,7,3,8,,"['MAPK14', 'TEK']","['Tyr', 'CMGC']",,,Single Stereoisomer,[],,,Cc1ccc(cc1)n2c(cc(n2)C(C)(C)C)NC(=O)NCc3cc(ccc3Oc4ccc5c(c4)cnn5CCO)F,LNMRSSIMGCDUTP-UHFFFAOYSA-N
16,Henatinib,,1.0,Jiangsu Hengrui Medicine,,,,0,468.2,2.0,97.9,5,3,5,,['KDR'],['Tyr'],,,Single Stereoisomer,[],,,Cc1c([nH]c2c1C(=O)N(CCC2)C[C@@H](CN3CCOCC3)O)/C=C\4/c5cc(ccc5NC4=O)F,MCTXSDCWFQAGFS-UEXNTNOUSA-N
17,Cenisertib,,1.0,EMD Serono,,,,0,451.2,2.5,99.4,7,3,6,,"['AURKA', 'AURKB', 'AURKC']",['Other'],,,Racemic Mixture,"['R-763', 'AS-703569']",,,Cc1cc(ccc1N2CCN(CC2)C)Nc3ncc(c(n3)N[C@@H]4[C@@H]5C[C@H]([C@@H]4C(=O)N)C=C5)F,KSOVGRCOLZZTPF-QMKUDKLTSA-N
18,Mubritinib,,1.0,Takeda,,,,1,468.2,6.1,66.0,6,0,10,,"['EGFR', 'ERBB2']",['Tyr'],,,Achiral Molecule,"['TAK-165', 'Mubritinib']",,,c1cc(ccc1CCCCn2ccnn2)OCc3coc(n3)/C=C/c4ccc(cc4)C(F)(F)F,ZTFBIUXIQYRUNT-MDWZMJQESA-N
19,Tafetinib,,1.0,Nanjing Yoko Biomedical,,,,0,424.2,3.7,77.2,3,3,6,,"['KDR', 'FLT4', 'FLT1']",['Tyr'],,,,[],,,CCN(CC)CCNC(=O)c1c([nH]c\2c1CCC/C2=C/3\c4cc(ccc4NC3=O)F)C,KGSRYTUWXUESJK-FXBPSFAMSA-N
20,Omipalisib,,1.0,GlaxosmithKline,ZIG,['3l08'],1.0,1,505.1,4.8,107.0,7,1,6,,"['PIK3CA', 'MTOR']",['Atypical'],,,Achiral Molecule,"['Omipalisib', 'GSK2126458']",,,COc1c(cc(cn1)c2ccc3c(c2)c(ccn3)c4ccnnc4)NS(=O)(=O)c5ccc(cc5F)F,CGBJSGAELGCMKE-UHFFFAOYSA-N
21,Pralsetinib,,1.5,Blueprint Medicines,,,,1,533.3,4.2,135.5,9,3,8,"Pralsetinib, also known as BLU-667, is a highly potent, selective, next generation RET inhibitor. BLU-667 is a potent and selective inhibitor of RET m utations, fusions, and predicted resistant mutants. RET fusions are key drivers of multiple cancers, including lung and thyroid cancer, and our research suggests that RET also plays a key role in some colon and breast cancers. By simultaneously targeting the primary driver and predicted resistant mutants that render cancer cells insensitive to treatment with currently approved drugs",,,,,,['BLU-667'],,,Cc1[nH]nc(c1)Nc2nc(nc(c2)C)[C@H]3CC[C@@](CC3)(OC)C(=O)N[C@H](c4cnc(cc4)n5ncc(c5)F)C,GBLBJPZSROAGMF-BATDWUPUSA-N
22,Derazantinib,,1.5,ArQule,,,,1,468.2,5.5,59.1,5,2,9,"Derazantinib (ARQ087) is an orally bioavailable, non-selective FGFR inhibitor being investigated for antineoplastic activity.",,,,,,[],,,COCCNCCc1cccc(c1)Nc2ncc3c(n2)-c4ccccc4[C@@H](C3)c5ccccc5F,KPJDVVCDVBFRMU-AREMUKBSSA-N
23,Vactosertib,,1.5,MedPacto,,,,0,399.2,4.2,83.8,6,2,5,"Vactosertib (EW-7197) acts as in inhibitor of transforming growth factor beta receptor 1B (ALK5) and activin A receptor type IB (ALK4). The compound i s potent, selective, and orally bioavailable, and exhibits experimental anti-tumour activity.",,,,,,[],,,Cc1cccc(n1)c2c(nc([nH]2)CNc3ccccc3F)c4ccc5ncnn5c4,FJCDSQATIJKQKA-UHFFFAOYSA-N
24,Ningetinib,,1.5,HEC Pharm,,,,2,556.2,5.4,107.6,8,2,8,"Ningetinib, also known as CT-053 or DE-120, is a VEGF and PDGF inhibitor potentially for the treatment of wet age-related macular degeneration.",,,,,,['NINGETINIB'],,,Cc1c(c(=O)n(n1C)c2ccccc2)C(=O)Nc3ccc(c(c3)F)Oc4ccnc5c4ccc(c5)OCC(C)(C)O,VQYYQSZNRVQLIS-UHFFFAOYSA-N
25,Voruciclib,,2.0,Piramal Enterprises,,,,0,469.1,4.3,94.1,6,3,3,,['CDK4'],['CMGC'],,,Single Stereoisomer,[],,,CN1CC[C@H]([C@@H]1CO)c2c(cc(c3c2oc(cc3=O)c4ccc(cc4Cl)C(F)(F)F)O)O,MRPGRAKIAJJGMM-OCCSQVGLSA-N
26,Tomivosertib,,2.0,Effector Therapeutics,N45,['6ck6'],,0,340.2,1.6,114.9,7,3,2,"Tomivosertib, also known as eFT508 is a MNK1/2 inhibitor. Tomivosertib binds to and inhibits the activity of MNK1 and 2. This prevents MNK1/2-mediated  signaling, and inhibits the phosphorylation of certain regulatory proteins, including eukaryotic translation initiation factor 4E (eIF4E), that regulate the translation of messenger RNAs (mRNAs) involved in tumor cell proliferation, angiogenesis, survival and immune signaling",,,,,,"['NK1', 'AND', 'MNK2']",,,Cc1cc(c(=O)n2c1C(=O)NC23CCCCC3)Nc4cc(ncn4)N,HKTBYUWLRDZAJK-UHFFFAOYSA-N
27,Ulixertinib,,2.0,BioMed Valley Discoveries,EVK,['6gdq'],,0,432.1,4.7,90.0,4,4,7,,"['MAPK1', 'MAPK3']",['CMGC'],,,Single Stereoisomer,"['VRT752271', 'VRT-752271', 'BVD-523']",,,CC(C)Nc1cc(c(cn1)Cl)c2cc([nH]c2)C(=O)N[C@H](CO)c3cccc(c3)Cl,KSERXGMCDHOLSS-LJQANCHMSA-N
28,Uprosertib,,2.0,GlaxoSmithKline,,,,0,428.1,3.6,86.1,5,2,6,,"['AKT1', 'AKT2', 'AKT3']",['AGC'],,,Single Stereoisomer,"['Uprosertib', 'GSK2141795C', 'GSK2141795']",,,Cn1c(c(cn1)Cl)c2cc(oc2Cl)C(=O)N[C@@H](Cc3ccc(c(c3)F)F)CN,AXTAPYRUEKNRBA-JTQLQIEISA-N
29,Ceralasertib,,2.0,Astrazeneca,,,,0,412.2,2.9,107.8,7,2,4,"Ceralasertib, also known as AZD6738, is an orally available morpholino-pyrimidine-based inhibitor of ataxia telangiectasia and rad3 related (ATR) kina se, with potential antineoplastic activity. Upon oral administration, ATR kinase inhibitor Ceralasertib selectively inhibits ATR activity by blocking the downstream phosphorylation of the serine/threonine protein kinase CHK1. This prevents ATR-mediated signaling, and results in the inhibition of DNA damage checkpoint activation, disruption of DNA damage repair, and the induction of tumor cell apoptosis.",,,,,,['AZD6738'],,,CC1COCCN1c2cc(nc(n2)c3cncc4c3cc[nH]4)C5(CC5)S(=N)(=O)C,DTTJKLNXNZAVSM-UHFFFAOYSA-N
30,Vistusertib,,2.0,Astrazeneca,,,,0,462.2,2.5,92.7,8,1,4,,['MTOR'],['Atypical'],,,Single Stereoisomer,"['AZD-2014', 'AZD2014', 'Vistusertib']",,,C[C@H]1COCCN1c2c3ccc(nc3nc(n2)N4CCOC[C@@H]4C)c5cccc(c5)C(=O)NC,JUSFANSTBFGBAF-IRXDYDNUSA-N
31,Selonsertib,,2.0,Gilead Sciences,NJV,['6oyt'],,0,445.2,4.7,90.5,7,1,6,,['MAP3K5'],['STE'],,,Achiral Molecule,"['GS-4997', 'Selonsertib']",,,Cc1cc(c(cc1n2cc(nc2)C3CC3)C(=O)Nc4cccc(n4)c5nncn5C(C)C)F,YIDDLAAKOYYGJG-UHFFFAOYSA-N
32,Pamapimod,,2.0,Hoffmann-La Roche,FLW,['3flw'],1.0,0,406.1,1.9,109.5,8,3,8,,"['MAPK14', 'MAPK11']",['CMGC'],,,Achiral Molecule,"['R-1503', 'JTT-705', 'Pamapimod', 'Ro-4402257']",,,Cn1c2c(cc(c1=O)Oc3ccc(cc3F)F)cnc(n2)NC(CCO)CCO,JYYLVUFNAHSSFE-UHFFFAOYSA-N
33,Berzosertib,,2.0,Vertex Pharmaceuticals,,,,0,463.2,3.9,124.0,8,2,7,,,,,,Achiral Molecule,"['VX-970', 'Berzosertib']",,,CC(C)S(=O)(=O)c1ccc(cc1)c2cnc(c(n2)c3cc(no3)c4ccc(cc4)CNC)N,JZCWLJDSIRUGIN-UHFFFAOYSA-N
34,Dilmapimod,,2.0,GlaxoSmithKline,,,,0,456.1,2.9,100.3,7,3,6,"Dilmapimod has been used in trials studying the treatment and diagnostic of Nerve Trauma, Inflammation, Pain, Neuropathic, Arthritis, Rheumatoid, and  Coronary Heart Disease, among others.","['MAPK14', 'MAPK11', 'MAPK13', 'MAPK12']",['CMGC'],,,Achiral Molecule,"['Dilmapimod', 'GW681323', 'SB-681323']",,,Cc1cc(ccc1c2c3ccc(=O)n(c3nc(n2)NC(CO)CO)c4c(cccc4F)F)F,ORVNHOYNEHYKJG-UHFFFAOYSA-N
35,Spebrutinib,,2.0,Celgene,,,,0,423.2,4.3,97.4,7,3,10,,['BTK'],['Tyr'],,,Achiral Molecule,"['CC-292', 'AVL-292', 'Spebrutinib']",,,COCCOc1ccc(cc1)Nc2ncc(c(n2)Nc3cccc(c3)NC(=O)C=C)F,KXBDTLQSDKGAEB-UHFFFAOYSA-N
36,Riviciclib,,2.0,Piramal Enterprises,,,,0,401.1,3.3,94.1,6,3,3,,"['CDK1', 'CDK4', 'CDK9']",['CMGC'],,,Racemic Mixture,[],,,CN1CC[C@H]([C@@H]1CO)c2c(cc(c3c2oc(cc3=O)c4ccccc4Cl)O)O,QLUYMIVVAYRECT-OCCSQVGLSA-N
37,Neflamapimod,,2.0,EIP Pharma,52P,"['3fc1', '3hp5', '3zsi']",,1,435.0,5.5,47.3,5,0,3,,['MAPK14'],['CMGC'],,,Achiral Molecule,"['Neflamapimod', 'VD-31', 'VRT-031745', 'VX-745', '745']",,,c1cc(c(c(c1)Cl)c2c3ccc(nn3cnc2=O)Sc4ccc(cc4F)F)Cl,VEPKQEUBKLEPRA-UHFFFAOYSA-N
38,Gandotinib,,2.0,Eli Lilly,,,,0,469.2,4.0,83.4,7,2,6,,['JAK2'],['Tyr'],,,Achiral Molecule,"['LY-2784544', 'Gandotinib']",,,Cc1cc(n[nH]1)Nc2cc(c3nc(c(n3n2)Cc4ccc(cc4F)Cl)C)CN5CCOCC5,SQSZANZGUXWJEA-UHFFFAOYSA-N
39,Apitolisib,,2.0,Hoffmann-La Roche,980,['3tl5'],,1,498.2,0.9,133.8,11,2,5,,"['PIK3CA', 'MTOR']",['Atypical'],,,Single Stereoisomer,"['GDC-0980.1', 'RG-7422', 'G-038390.1', 'GDC-0980', 'Apitolisib', 'G-038390']",,,Cc1c(sc2c1nc(nc2N3CCOCC3)c4cnc(nc4)N)CN5CCN(CC5)C(=O)[C@H](C)O,YOVVNQKCSKSHKT-HNNXBMFYSA-N
40,Rabusertib,,2.0,Eli Lilly,,,,0,435.1,2.9,97.4,6,3,5,,['CHEK1'],['CAMK'],,,Single Stereoisomer,"['Rabusertib', 'LY-2603618', 'IC-83']",,,Cc1cc(c(cc1Br)NC(=O)Nc2cnc(cn2)C)OC[C@@H]3CNCCO3,SYYBDNPGDKKJDU-ZDUSSCGKSA-N
41,Dactolisib,,2.0,Novartis,,,,1,469.2,5.9,76.5,6,0,3,,"['PIK3CA', 'PIK3CB', 'PIK3CG', 'PIK3CD', 'MTOR']",['Atypical'],,,Achiral Molecule,"['Dactolisib', 'NVP-BEZ235-NX', 'BEZ-235', 'NVP-BEZ235']",,,CC(C)(C#N)c1ccc(cc1)n2c3c4cc(ccc4ncc3n(c2=O)C)c5cc6ccccc6nc5,JOGKUKXHTYWRGZ-UHFFFAOYSA-N
42,Pictilisib,,2.0,Hoffmann-La Roche,GD9,"['2wxp', '2y3a', '3dbs']",1.0,1,513.2,2.1,107.6,9,1,5,,"['PIK3CA', 'PIK3CB', 'PIK3CD', 'PIK3CG']",['Atypical'],,,Achiral Molecule,"['RG-7321', 'GDC-0941', 'Pictilisib']",,,CS(=O)(=O)N1CCN(CC1)Cc2cc3c(s2)c(nc(n3)c4cccc5c4cn[nH]5)N6CCOCC6,LHNIIDJUOCFXAP-UHFFFAOYSA-N
43,Bimiralisib,,2.0,Piqur Therapeutics,A3W,['5oq4'],,0,411.2,1.0,103.2,8,2,3,"Bimiralisib (PQR309) is a novel dual inhibitor of phosphoinositol 3-kinase (PI3K) and mechanistic target of rapamycin (mTOR) kinases, with expected ut ility as an anti-cancer agent.",,,,,,"['PQR309', 'BIMIRALISIB']",,,c1c(c(c[nH]c1=N)c2nc(nc(n2)N3CCOCC3)N4CCOCC4)C(F)(F)F,ADGGYDAFIHSYFI-UHFFFAOYSA-N
44,Foretinib,,2.0,GlaxoSmithKline,88Z,"['3lq8', '5ia4', '6i2y', '6sd9', '6sdc']",2.0,2,632.2,5.8,111.2,8,2,12,,"['MET', 'KDR']",['Tyr'],,,Achiral Molecule,"['EXEL-2880', 'Foretinib', 'GSK1363089G', 'GSK1363089', 'GSK-1363089', 'XL-880', 'GSK089']",,,COc1cc2c(ccnc2cc1OCCCN3CCOCC3)Oc4ccc(cc4F)NC(=O)C5(CC5)C(=O)Nc6ccc(cc6)F,CXQHYVUVSFXTMY-UHFFFAOYSA-N
45,Afuresertib,,2.0,GlaxoSmithKline,,,,0,426.0,3.9,72.9,5,2,6,,"['AKT1', 'AKT2', 'AKT3']",['AGC'],,,Single Stereoisomer,"['GSK2110183', 'Afuresertib', 'GSK2110183C']",,,Cn1c(c(cn1)Cl)c2cc(sc2Cl)C(=O)N[C@@H](Cc3cccc(c3)F)CN,AFJRDFWMXUECEW-LBPRGKRZSA-N
46,Lucitanib,,2.0,Clovis Oncology,3ZC,['4rwl'],1.0,0,443.2,4.4,95.7,6,2,7,,"['FLT1', 'KDR', 'FLT4', 'FGFR1', 'FGFR2']",['Tyr'],,,Achiral Molecule,"['E-3810', 'CO-3810', 'Lucitanib', 'S-80881', 'AL-3810']",,,CNC(=O)c1cccc2c1ccc(c2)Oc3ccnc4c3cc(c(c4)OCC5(CC5)N)OC,CUDVHEFYRIWYQD-UHFFFAOYSA-N
47,Adavosertib,,2.0,Astrazeneca,8X7,"['5v5y', '5vd0', '5vdk']",1.0,1,500.3,2.9,104.3,10,2,7,,['WEE1'],['Other'],,,,"['AZD-1775', 'MK-1775']",,,CC(C)(c1cccc(n1)n2c3c(cnc(n3)Nc4ccc(cc4)N5CCN(CC5)C)c(=O)n2CC=C)O,BKWJAKQVGHWELA-UHFFFAOYSA-N
48,Defactinib,,2.0,Verastem,7KD,['5mah'],1.0,1,510.1,2.4,142.1,9,3,8,,"['PTK2', 'PTK2B']",['Tyr'],,,Achiral Molecule,"['PF-04554878', 'VS-6063', 'Defactinib']",,,CNC(=O)c1ccc(cc1)Nc2ncc(c(n2)NCc3c(nccn3)N(C)S(=O)(=O)C)C(F)(F)F,FWLMVFUGMHIOAA-UHFFFAOYSA-N
49,Bafetinib,,2.0,Innovive Pharmaceuticals,406,['2e2b'],2.0,2,576.3,5.4,99.2,8,2,8,,"['LYN', 'ABL1']",['Tyr'],,,Single Stereoisomer,"['CNS-9', 'Bafetinib', 'NS-187', 'INNO-406']",,,Cc1ccc(cc1Nc2nccc(n2)c3cncnc3)NC(=O)c4ccc(c(c4)C(F)(F)F)CN5CC[C@@H](C5)N(C)C,ZGBAJMQHJDFTQJ-DEOSSOPVSA-N
50,Merestinib,,2.0,Eli Lilly,L1X,['4eev'],2.0,2,552.2,5.7,106.8,7,2,6,,['MET'],['Tyr'],,,Achiral Molecule,"['Merestinib', 'LY-2801653']",,,Cc1ccc(c(=O)n1c2ccc(cc2)F)C(=O)Nc3ccc(c(c3)F)Oc4cc5cnn(c5cc4c6c[nH]nc6)C,QHADVLVFMKEIIP-UHFFFAOYSA-N
51,Entospletinib,,2.0,Gilead Sciences,CG9,['4puz'],1.0,0,411.2,3.9,83.4,7,2,4,,['SYK'],['Tyr'],,,Achiral Molecule,"['GS-9973', 'Entospletinib']",,,c1cc(ccc1Nc2c3nccn3cc(n2)c4ccc5cn[nH]c5c4)N6CCOCC6,XSMSNFMDVXXHGJ-UHFFFAOYSA-N
52,Galunisertib,,2.0,Eli Lilly,,,,0,369.2,3.5,86.7,5,1,3,,['TGFBR1'],['TKL'],,,Achiral Molecule,"['Galunisertib', 'LY-2157299']",,,Cc1cccc(n1)c2c(c3n(n2)CCC3)c4ccnc5c4cc(cc5)C(=O)N,IVRXNBXKWIJUQB-UHFFFAOYSA-N
53,Ilorasertib,,2.0,Abbott Laboratories,,,,1,488.1,5.2,118.1,7,4,6,,"['AURKA', 'AURKB', 'AURKC', 'FLT1', 'PDGFRA', 'PDGFRB']","['Tyr', 'Other']",,,Achiral Molecule,"['A-968660', 'ABT-348', 'Ilorasertib']",,,c1cc(cc(c1)F)NC(=O)Nc2ccc(cc2)c3csc4c3c(ncc4c5cnn(c5)CCO)N,WPHKIQPVPYJNAX-UHFFFAOYSA-N
54,Amcasertib,,2.0,Boston Biomedical,,,,2,539.2,6.0,90.1,5,3,9,,['PDGFRA'],['Tyr'],,,Achiral Molecule,"['BBI-503', 'Amcasertib']",,,CCN(CC)CCNC(=O)c1c(c([nH]c1C)/C=C\2/c3cc(ccc3NC2=O)c4csc(n4)c5ccccc5)C,QDWKGEFGLQMDAM-ULJHMMPZSA-N
55,Amuvatinib,,2.0,Supergen,,,,0,447.1,3.3,75.9,7,1,3,"Amuvatinib is a selective multi-targeted tyrosine kinase inhibitor that suppresses c-MET, c-RET and the mutant forms of c-KIT, PDGFR and FLT3. Amuvati nib also suppresses Rad51 protein, a critical comp\nonent of double-stranded DNA repair in cancer cells.","['KIT', 'MET', 'RET', 'FLT3', 'PDGFRB']",['Tyr'],,,Achiral Molecule,"['MP-470', 'HPK56', 'Amuvatinib', 'HPK-56']",,,c1ccc2c(c1)c3c(o2)c(ncn3)N4CCN(CC4)C(=S)NCc5ccc6c(c5)OCO6,FOFDIMHVKGYHRU-UHFFFAOYSA-N
56,Evobrutinib,,2.0,Merck,MZJ,['6omu'],,0,429.2,4.4,93.4,6,2,7,,['BTK'],['Tyr'],,,,['EVOBRUTINIB'],,,C=CC(=O)N1CCC(CC1)CNc2c(c(ncn2)N)c3ccc(cc3)Oc4ccccc4,QUIWHXQETADMGN-UHFFFAOYSA-N
57,Glesatinib,,2.0,Mirati Therapeutics,,,,2,619.2,6.2,97.4,8,3,11,,"['MET', 'TEK', 'FLT1', 'KDR', 'FLT4', 'MST1R']",['Tyr'],,,Achiral Molecule,"['MG90265H9', 'MG90265gly', 'MGCD265', 'MG90265', 'MG90265X', 'Glesatinib']",,,COCCNCc1ccc(nc1)c2cc3c(s2)c(ccn3)Oc4ccc(cc4F)NC(=S)NC(=O)Cc5ccc(cc5)F,YRCHYHRCBXNYNU-UHFFFAOYSA-N
58,Bemcentinib,,2.0,BerGenBio,,,,1,506.3,4.9,97.8,8,2,4,,['AXL'],['Tyr'],,,,"['BGB324;', 'KEYTRUDA', 'BEMCENTINIB']",,,c1ccc-2c(c1)CCCc3c2nnc(c3)n4c(nc(n4)Nc5ccc6c(c5)CC[C@H](CC6)N7CCCC7)N,KXMZDGSRSGHMMK-VWLOTQADSA-N
59,Gedatolisib,,2.0,Pfizer,,,,1,615.3,3.0,128.3,10,2,7,,"['PIK3CA', 'PIK3CB', 'PIK3CG', 'PIK3CD', 'MTOR']",['Atypical'],,,Achiral Molecule,"['PKI-587', 'Gedatolisib', 'PF-05212384']",,,CN(C)C1CCN(CC1)C(=O)c2ccc(cc2)NC(=O)Nc3ccc(cc3)c4nc(nc(n4)N5CCOCC5)N6CCOCC6,DWZAEMINVBZMHQ-UHFFFAOYSA-N
60,Capivasertib,,2.0,Astrazeneca,0XZ,['4gv1'],,0,428.2,2.1,120.2,6,4,6,,['AKT1'],['AGC'],,,,['AZD-5363'],,,c1cc(ccc1[C@H](CCO)NC(=O)C2(CCN(CC2)c3c4cc[nH]c4ncn3)N)Cl,JDUBGYFRJFOXQC-KRWDZBQOSA-N
61,Telatinib,,2.0,Bayer,,,,0,409.1,4.0,102.2,7,2,6,,"['KDR', 'FLT4']",['Tyr'],,,Achiral Molecule,"['BAY-57-9352', 'Telatinib', 'BAY-579352']",,,CNC(=O)c1cc(ccn1)COc2c3c(cco3)c(nn2)Nc4ccc(cc4)Cl,QFCXANHHBCGMAS-UHFFFAOYSA-N
62,Pilaralisib,,2.0,Sanofi,,,,1,540.1,4.5,148.3,8,4,8,,"['PIK3CA', 'PIK3CB', 'PIK3CD', 'PIK3CG']",['Atypical'],,,Achiral Molecule,"['Pilaralisib', 'SAR-245408', 'XL-147']",,,CC(C)(C(=O)Nc1cccc(c1)S(=O)(=O)Nc2c(nc3ccccc3n2)Nc4cc(ccc4Cl)OC)N,QINPEPAQOBZPOF-UHFFFAOYSA-N
63,Bentamapimod,,2.0,PregLem,,,,0,457.2,4.2,84.2,8,0,7,,"['MAPK8', 'MAPK9']",['CMGC'],,,Racemic Mixture,"['PGL-5001', 'Bentamapimod', 'AS-602801']",,,N#CC(c1nc2ccccc2s1)c5nc(OCc3ccc(cc3)CN4CCOCC4)ncc5,XCPPIJCBCWUBNT-UHFFFAOYSA-N
64,Ralimetinib,,2.0,Eli Lilly,,,,1,420.2,5.6,85.4,5,2,3,,"['MAPK14', 'MAPK11']",['CMGC'],,,Achiral Molecule,"['LY-2228820', 'LY-22288220', 'Ralimetinib']",,,CC(C)(C)Cn1c2c(ccc(n2)c3c(nc([nH]3)C(C)(C)C)c4ccc(cc4)F)nc1N,XPPBBJCBDOEXDN-UHFFFAOYSA-N
65,Rebastinib,,2.0,Deciphera Pharmaceuticals,919,"['3qri', '3qrj', '5g6v', '6cnh', '6mwe']",2.0,2,553.2,6.0,123.1,7,3,6,,"['FLT3', 'TEK', 'KDR', 'LYN', 'BCR', 'ABL1', 'NTRK1']","['Atypical', 'Tyr']",,,Achiral Molecule,"['DP-1919', 'DP-1919', 'DCC-2036', 'Rebastinib']",,,CC(C)(C)c1cc(n(n1)c2ccc3c(c2)cccn3)NC(=O)Nc4ccc(cc4F)Oc5ccnc(c5)C(=O)NC,WVXNSAVVKYZVOE-UHFFFAOYSA-N
66,Refametinib,,2.0,Bayer,VRA,['3e8n'],,1,572.0,3.5,107.9,6,4,9,,['MAP2K1'],['STE'],,,Single Stereoisomer,"['BAY-86-9766', 'Refametinib', 'RDEA-119']",,,COc1cc(c(c(c1NS(=O)(=O)C2(CC2)C[C@@H](CO)O)Nc3ccc(cc3F)I)F)F,RDSACQWTXKSHJT-NSHDSACASA-N
67,Tepotinib,,2.0,Merck,3E8,['4r1v'],1.0,0,492.2,4.0,96.9,8,0,7,,['MET'],['Tyr'],,,Achiral Molecule,"['MSC-2156119', 'Tepotinib', 'MSC-2156119J', 'EMD-1214063']",,,CN1CCC(CC1)COc2cnc(nc2)c3cccc(c3)Cn4c(=O)ccc(n4)c5cccc(c5)C#N,AHYMHWXQRWRBKT-UHFFFAOYSA-N
68,Ripasudil,,2.0,Kowa Pharmaceutical,,,,0,323.1,1.7,62.3,4,1,2,,,,,,,['RIPASUDIL'],,,C[C@H]1CNCCCN1S(=O)(=O)c2cccc3c2c(cnc3)F,QSKQVZWVLOIIEV-NSHDSACASA-N
69,Rogaratinib,,2.0,Bayer,,,,0,466.2,2.6,107.0,9,2,6,Rogaratinib (BAY-1163877) is a FGFR-selective kinase inhibitor that is being investigated for antineoplastic activity.,,,,,,"['ROGARATINIB', 'BAY', '1163877']",,,Cc1cc2cc(sc2c(c1)OC)c3c(c(n4c3c(ncn4)N)CN5CCNC(=O)C5)COC,HNLRRJSKGXOYNO-UHFFFAOYSA-N
70,Seliciclib,,2.0,Cyclacel pharmaceuticals,RRC,"['1unl', '1ygk', '2a4l', '3ddq']",1.0,0,354.2,3.2,87.9,7,3,8,,"['CDK2', 'CDK7', 'CDK9']",['CMGC'],,,Single Stereoisomer,"['Seliciclib', 'CYC-202', 'AL-39256']",,,CC[C@H](CO)Nc1nc(NCc2ccccc2)c3ncn(C(C)C)c3n1,BTIHMVBBUGXLCJ-OAHLLOKOSA-N
71,Tarloxotinib,,2.0,Threshold Pharmaceuticals,,,,1,679.0,1.6,140.8,9,2,9,,['EGFR'],['Tyr'],,,,[],,,Cn1cnc(c1C[N+](C)(C)C/C=C/C(=O)Nc2cc3c(cn2)ncnc3Nc4ccc(c(c4)Br)Cl)[N+](=O)[O-].[Br-],WAKIMVYUBWMMHJ-FXRZFVDSSA-N
72,Tandutinib,,2.0,Takeda,,,,2,562.3,5.0,92.3,8,1,10,Investigated for use/treatment in leukemia (myeloid).,"['FLT3', 'PDGFD']","['(*)', 'Tyr']",,,Achiral Molecule,"['Tandutinib', 'MLN-0518', 'CT-53518', 'MLN-518']",,,CC(C)Oc1ccc(cc1)NC(=O)N2CCN(CC2)c3c4cc(c(cc4ncn3)OCCCN5CCCCC5)OC,UXXQOJXBIDBUAC-UHFFFAOYSA-N
73,Roniciclib,,2.0,Bayer,,,,0,430.1,4.0,108.2,7,3,7,,"['CDK1', 'CDK2', 'CDK4', 'CDK9']",['CMGC'],,,Single Stereoisomer,[],,,C[C@H]([C@@H](C)Oc1c(cnc(n1)Nc2ccc(cc2)[S@](=N)(=O)C3CC3)C(F)(F)F)O,UELYDGOOJPRWGF-SRQXXRKNSA-N
74,Sotrastaurin,,2.0,Novartis,LW4,['3iw4'],,0,438.2,2.4,94.2,6,2,3,,,,,,Achiral Molecule,"['AEB-071', 'NVP-AEB071', 'AEB071', 'Sotrastaurin']",,,CN1CCN(CC1)c2nc3ccccc3c(n2)C4=C(C(=O)NC4=O)c5c[nH]c6c5cccc6,OAVGBZOFDPFGPJ-UHFFFAOYSA-N
75,Sapanisertib,,2.0,Takeda,FE5,['6gvf'],,0,309.1,2.4,121.7,8,2,2,,['MTOR'],['Atypical'],,,Achiral Molecule,"['MLN-0128', 'Sapanisertib', 'TAK-228']",,,CC(C)n1c2c(c(n1)c3ccc4c(c3)nc(o4)N)c(ncn2)N,GYLDXIAOMVERTK-UHFFFAOYSA-N
76,Samotolisib,,2.0,Eli Lilly,,,,0,406.2,3.2,82.2,7,1,5,"LY3023414 is a dual inhibitor of phosphoinositide 3-kinase α (PI3Kα) and the serine/threonine kinase mTOR (mechanistic target of rapamycin ), with potential antineoplastic activity.",,,,,,"['LY-3023414', 'LY', '3023414', 'WHO', '10889', 'LY3023414']",,,C[C@@H](Cn1c2c3cc(ccc3ncc2n(c1=O)C)c4cc(cnc4)C(C)(C)O)OC,ACCFLVVUVBJNGT-AWEZNQCLSA-N
77,Milciclib,,2.0,Nerviano Medical Sciences,P48,"['2wih', '5vc6', '5vd1']",1.0,0,460.3,2.6,91.2,8,2,4,,"['CDK1', 'NTRK1']","['Tyr', 'CMGC']",,,Achiral Molecule,"['PHA-848125', 'Milciclib']",,,CC1(Cc2cnc(nc2-c3c1c(nn3C)C(=O)NC)Nc4ccc(cc4)N5CCN(CC5)C)C,RXZMYLDMFYNEIM-UHFFFAOYSA-N
78,Infigratinib,,2.0,Novartis,07J,['3tt0'],1.0,2,559.2,5.4,95.1,8,2,8,,"['FGFR1', 'FGFR2', 'FGFR3']",['Tyr'],,,,"['BGJ-398', 'NVP-BGJ398']",,,CCN1CCN(CC1)c2ccc(cc2)Nc3cc(ncn3)N(C)C(=O)Nc4c(c(cc(c4Cl)OC)OC)Cl,QADPYRIHXKWUSV-UHFFFAOYSA-N
79,Trilaciclib,,2.0,G1 Therapeutics,,,,0,446.3,2.7,91.2,8,2,3,,"['CDK4', 'CDK6']",['CMGC'],,,Achiral Molecule,"['G1T28', 'Trilaciclib']",,,CN1CCN(CC1)c2ccc(nc2)Nc3ncc4cc5n(c4n3)C6(CCCCC6)CNC5=O,PDGKHKMBHVFCMG-UHFFFAOYSA-N
80,Prexasertib,,2.0,Eli Lilly,,,,0,365.2,2.2,134.8,8,3,8,,"['CHEK1', 'CHEK2']",['CAMK'],,,Achiral Molecule,"['LY-2606368', 'Prexasertib']",,,COc1cccc(c1c2cc(n[nH]2)Nc3cnc(cn3)C#N)OCCCN,DOTGPNHGTYJDEP-UHFFFAOYSA-N
81,Poziotinib,,2.0,Hanmi Pharmaceutical,,,,1,490.1,5.4,76.6,6,1,6,,['EGFR'],['Tyr'],,,Achiral Molecule,"['NOV-120101', 'Poziotinib', 'HM-781-36B']",,,COc1cc2c(cc1OC3CCN(CC3)C(=O)C=C)c(ncn2)Nc4ccc(c(c4F)Cl)Cl,LPFWVDIFUFFKJU-UHFFFAOYSA-N
82,Golvatinib,,2.0,Eisai,GV0,['5ia5'],2.0,1,633.3,4.8,119.1,7,3,8,,"['MET', 'KDR']",['Tyr'],,,Achiral Molecule,"['E-7050', 'Golvatinib', 'E7050']",,,CN1CCN(CC1)C2CCN(CC2)C(=O)Nc3cc(ccn3)Oc4ccc(c(c4)F)NC(=O)C5(CC5)C(=O)Nc6ccc(cc6)F,UQRCJCNVNUFYDX-UHFFFAOYSA-N
83,Pimasertib,,2.0,Merck,,,,0,431.0,1.7,94.5,5,4,6,,"['MAP2K1', 'MAP2K2']",['STE'],,,Single Stereoisomer,"['MSC1936369A;', 'AS703026;', 'EMD', '1036239', 'AS-703026', 'MSC-1936369B', 'EMD', '1036239', 'Pimasertib']",,,c1cc(c(cc1I)F)Nc2cnccc2C(=O)NC[C@@H](CO)O,VIUAUNHCRHHYNE-JTQLQIEISA-N
84,Acalisib,,2.0,Gilead Sciences,,,,0,401.1,3.4,101.4,7,2,4,,['PIK3CA'],['Atypical'],,,Single Stereoisomer,['CAL-120'],,,C[C@@H](c1nc2ccc(cc2c(=O)n1c3ccccc3)F)Nc4c5c(nc[nH]5)ncn4,DOCINCLJNAXZQF-LBPRGKRZSA-N
85,Sapitinib,,2.0,Astrazeneca,,,,0,473.2,3.8,88.6,7,2,7,,"['EGFR', 'ERBB2', 'ERBB4', 'ERBB3']",['Tyr'],,,Achiral Molecule,"['Sapitinib', 'AZD-8931']",,,CNC(=O)CN1CCC(CC1)Oc2cc3c(cc2OC)ncnc3Nc4cccc(c4F)Cl,DFJSJLGUIXFDJP-UHFFFAOYSA-N
86,Tozasertib,,2.0,Merck,VX6,"['2f4j', '2xyn', '3amb', '3e5a', '4af3', '4b8m', '4jbq', '4zog', '5wnm', '6brj', '6gr9']",1.0,0,464.2,3.5,102.1,8,3,7,,"['AURKA', 'AURKB', 'AURKC']",['Other'],,,Achiral Molecule,"['VX-680', 'MK-0457', 'Tozasertib', 'VX-68', 'MK-045']",,,Cc1cc(n[nH]1)Nc2cc(nc(n2)Sc3ccc(cc3)NC(=O)C4CC4)N5CCN(CC5)C,GCIKSSRWRFVXBI-UHFFFAOYSA-N
87,Silmitasertib,,2.0,Senhwa Biosciences,3NG,"['3nga', '3pe1', '5o11', '6fyl', '6fyp', '6fyv', '6hmb', '6isj', '6k3l', '6khd', '6khe', '6khf', '6p5s']",1.0,0,349.1,4.9,75.1,4,2,3,,"['CSNK2A1', 'CSNK2A2']",['Other'],,,Achiral Molecule,"['Silmitasertib', 'CX-4945']",,,c1cc(cc(c1)Cl)Nc2c3ccncc3c4ccc(cc4n2)C(=O)O,MUOKSQABCJCOPU-UHFFFAOYSA-N
88,Tanzisertib,,2.0,Celgene,KBI,['3tti'],1.0,0,448.2,3.7,97.1,8,3,5,,['MAPK8'],['CMGC'],,,Single Stereoisomer,"['Tanzisertib', 'JNK-930', 'CC-930']",,,c1c(c(c(cc1F)F)Nc2n(c3nc(ncc3n2)N[C@H]4CC[C@@H](CC4)O)[C@@H]5COCC5)F,IBGLGMOPHJQDJB-IHRRRGAJSA-N
89,Voxtalisib,,2.0,Sanofi,,,,0,270.1,1.1,102.5,6,2,2,,"['PIK3CA', 'MTOR']",['Atypical'],,,Achiral Molecule,"['SAR-245409', 'Voxtalisib', 'XL-765']",,,CCn1c2c(cc(c1=O)c3ccn[nH]3)c(nc(n2)N)C,RGHYDLZMTYDBDT-UHFFFAOYSA-N
90,Acumapimod,,2.0,Mereo BioPharma,,,,0,385.2,2.8,113.8,6,2,5,,"['MAPK14', 'MAPK11', 'MAPK13', 'MAPK12']",['CMGC'],,,Single Stereoisomer,[],,,Cc1ccc(cc1n2c(c(cn2)C(=O)c3cccc(c3)C#N)N)C(=O)NC4CC4,VGUSQKZDZHAAEE-UHFFFAOYSA-N
91,Danusertib,,2.0,Nerviano Medical Sciences,627,"['2j50', '2v7a', '4qo9', '5i9z']",1.0,0,474.2,2.6,93.8,6,2,6,,"['AURKA', 'AURKB', 'AURKC']",['Other'],,,Single Stereoisomer,"['Danusertib', 'PHA-739358']",,,CN1CCN(CC1)c2ccc(cc2)C(=O)Nc3c4c([nH]n3)CN(C4)C(=O)[C@@H](c5ccccc5)OC,XKFTZKGMDDZMJI-HSZRJFAPSA-N
92,Verosudil,,2.0,Aerie Pharmaceutical,,,,0,327.1,2.8,65.2,4,2,4,,,,,,Racemic Mixture,"['Verosudil', 'AR-12286']",,,CN(C)C(c1ccsc1)C(=O)Nc2ccc3c(c2)cc[nH]c3=O,VDYRZXYYQMMFJW-UHFFFAOYSA-N
93,Solcitinib,,2.0,GlaxoSmithKline,,,,0,389.2,3.2,79.6,5,1,4,,['JAK1'],['Tyr'],,,Achiral Molecule,"['GLPG-0788', 'GSK2586184A', 'Solcitinib', 'GSK2586184', 'G-154578', 'GLPG-0778']",,,CC1(CN(C1)C(=O)c2ccc(cc2)c3cccc4n3nc(n4)NC(=O)C5CC5)C,MPYACSQFXVMWNO-UHFFFAOYSA-N
94,Talmapimod,,2.0,Scios inc,469,"['3hub', '3zsh']",1.0,1,512.2,4.0,65.9,5,0,5,Investigated for use/treatment in pain (acute or chronic) and rheumatoid arthritis.,['MAPK14'],['CMGC'],,,Single Stereoisomer,"['Talmapimod', 'SCIO-469']",,,C[C@@H]1CN([C@H](CN1C(=O)c2cc3c(cc2Cl)n(cc3C(=O)C(=O)N(C)C)C)C)Cc4ccc(cc4)F,ZMELOYOKMZBMRB-DLBZAZTESA-N
95,Tesevatinib,,2.0,Kadmon Corporation,,,,1,490.1,5.8,59.5,6,1,6,,"['EGFR', 'ERBB2', 'KDR', 'FLT4', 'EPHB4']",['Tyr'],,,Racemic Mixture,"['Tesevatinib', 'XL-647', 'KD-020', 'KD-019']",,,CN1C[C@H]2C[C@H](C[C@H]2C1)COc3cc4c(cc3OC)c(ncn4)Nc5ccc(c(c5F)Cl)Cl,HVXKQKFEHMGHSL-QKDCVEJESA-N
96,Olmutinib,,2.0,Hanmi Pharmaceutical,,,,1,486.2,5.1,82.6,8,2,7,For use in treatment of metastatic T790M mutation positive non-small cell lung cancer,['EGFR'],['Tyr'],,,Achiral Molecule,"['BI', '1482694', 'Olmutinib', 'HM61713', 'HM-61713']",,,CN1CCN(CC1)c2ccc(cc2)Nc3nc4ccsc4c(n3)Oc5cccc(c5)NC(=O)C=C,FDMQDKQUTRLUBU-UHFFFAOYSA-N
97,Parsaclisib,,2.0,Incyte Corporation,,,,0,432.1,3.1,107.9,7,2,5,"Parsaclisib (INCB050465) is a PI3Kδ inhibitor that was developed by Incyte Corporation as an antineoplastic and immunomodulatory agent, as claim ed in their patent WO2014134426A1 [ 1 ]. The chemical structure is one of those claimed in patent WO2013033569A1, but it is not clear which example it is from a mixture of diastereoisomers 345-348 (although 347 and 348 had the highest inhibitory potency  vs . PI3Kδ and 347 was tested  in vivo  [ 2 ].",,,,,,['INCB050465'],,,CCOc1c(cc(c(c1[C@H]2CC(=O)NC2)F)Cl)[C@H](C)n3c4c(c(n3)C)c(ncn4)N,ZQPDJCIXJHUERQ-QWRGUYRKSA-N
98,Pelitinib,,2.0,Wyeth,93J,['5vcw'],1.0,1,467.2,5.1,90.3,6,2,8,,"['EGFR', 'ERBB2']",['Tyr'],,,Achiral Molecule,"['WAY-EKB-569', 'EKB-569', 'Pelitinib']",,,CCOc1cc2c(cc1NC(=O)/C=C/CN(C)C)c(c(cn2)C#N)Nc3ccc(c(c3)Cl)F,WVUNYSQLFKLYNI-AATRIKPKSA-N
99,Sonolisib,,2.0,Cascadian Therapeutics,,,,1,525.2,3.1,119.4,9,1,8,,"['PIK3CA', 'PIK3CB', 'PIK3CG']",['Atypical'],,,Single Stereoisomer,"['Sonolisib', 'PX-866']",,,CC(=O)O[C@@H]1C[C@]2([C@@H](CCC2=O)C3=C1[C@]4([C@H](OC(=O)/C(=C/N(CC=C)CC=C)/C4=C(C3=O)O)COC)C)C,QIUASFSNWYMDFS-NILGECQDSA-N
100,Decernotinib,,2.0,Vertex Pharmaceuticals,VJK,['4yti'],1.0,0,392.2,3.3,95.6,5,3,6,,['JAK3'],['Tyr'],,,Single Stereoisomer,"['VRT-831509', 'Adelatinib', 'VX-509', 'Decernotinib']",,,CC[C@](C)(C(=O)NCC(F)(F)F)Nc1ccnc(n1)c2c[nH]c3c2cccn3,ASUGUQWIHMTFJL-QGZVFWFLSA-N
101,Doramapimod,,2.0,Boehringer Ingelheim,B96,"['1kv2', '3fzs', '3npc', '4jvg', '4twn', '5n66', '6gtt']",2.0,2,527.3,6.0,80.7,6,2,7,,['MAPK14'],['CMGC'],,,Achiral Molecule,"['Doramapimod', 'BIRB-796']",,,Cc1ccc(cc1)n2c(cc(n2)C(C)(C)C)NC(=O)Nc3ccc(c4c3cccc4)OCCN5CCOCC5,MVCOAUNKQVWQHZ-UHFFFAOYSA-N
102,Tucatinib,,2.0,Array BioPharma,,,,1,480.2,5.1,110.9,10,2,5,,['ERBB2'],['Tyr'],,,Achiral Molecule,"['Tucatinib', 'ONT-380', 'ARRY-380']",,,Cc1cc(ccc1Oc2ccn3c(c2)ncn3)Nc4c5cc(ccc5ncn4)NC6=NC(CO6)(C)C,SDEAXTCZPQIFQM-UHFFFAOYSA-N
103,Tamatinib,,2.0,Rigel Pharmaceuticals,585,"['3fqs', '3piy']",1.0,0,470.2,3.6,128.8,10,3,7,,['SYK'],['Tyr'],,,,['R-406'],,,CC1(C(=O)Nc2c(ccc(n2)Nc3c(cnc(n3)Nc4cc(c(c(c4)OC)OC)OC)F)O1)C,NHHQJBCNYHBUSI-UHFFFAOYSA-N
104,Varlitinib,,2.5,Array Biopharma,,,,1,466.1,5.2,93.5,9,2,6,Investigated for use/treatment in cancer/tumors (unspecified).,"['EGFR', 'ERBB2']",['Tyr'],,,Single Stereoisomer,"['ARRY-543', 'ASLAN-001', 'Varlitinib', 'ARRY-334543']",,,C[C@@H]1COC(=N1)Nc2ccc3c(c2)c(ncn3)Nc4ccc(c(c4)Cl)OCc5nccs5,UWXSAYUXVSFDBQ-CYBMUJFWSA-N
105,Cerdulatinib,,2.5,Portola pharmaceuticals,,,,0,445.2,1.4,133.6,8,3,8,,"['JAK1', 'SYK']",['Tyr'],,,Single Stereoisomer,['PRT-062070'],,,CCS(=O)(=O)N1CCN(CC1)c2ccc(cc2)Nc3ncc(c(n3)NC4CC4)C(=O)N,BGLPECHZZQDNCD-UHFFFAOYSA-N
106,Flumatinib,,3.0,Jiangsu Hengrui Medicine,,,,2,562.2,5.0,99.2,8,2,7,,"['BCR', 'ABL1', 'PDGFRB', 'KIT']","['Atypical', 'Tyr']",,,Achiral Molecule,"['HHGV-678', 'Flumatinib']",,,Cc1c(cc(cn1)NC(=O)c2ccc(c(c2)C(F)(F)F)CN3CCN(CC3)C)Nc4nccc(n4)c5cccnc5,BJCJYEYYYGBROF-UHFFFAOYSA-N
107,Linifanib,,3.0,Abbott Laboratories,,,,0,375.1,4.9,95.8,3,4,3,,"['FLT3', 'CSF1R', 'KDR']",['Tyr'],,,Achiral Molecule,"['ABT-869', 'RG-3635', 'Linifanib', 'AL-39324']",,,Cc1ccc(c(c1)NC(=O)Nc2ccc(cc2)c3cccc4c3c(n[nH]4)N)F,MPVGZUGXCQEXTM-UHFFFAOYSA-N
108,Linsitinib,,3.0,Osi Pharmaceuticals,,,,0,421.2,4.8,89.3,6,2,3,,['IGF1R'],['Tyr'],,,Single Stereoisomer,"['Linsitinib', 'ASP-7487', 'OSI-906', 'OSI-906AA']",,,C[C@]1(C[C@@H](C1)c2n3c(c(ncc3)N)c(n2)c4cc5nc(ccc5cc4)c6ccccc6)O,PKCDDUHJAFVJJB-VLZXCDOPSA-N
109,Pacritinib,,3.0,Cell Therapeutics,6T3,['5lbz'],,0,472.2,5.0,68.7,7,1,4,,['JAK2'],['Tyr'],,,Achiral Molecule,"['ONX-0803', 'SB-1518', 'SB1518', 'Pacritinib']",,,c1cc2cc(c1)-c3ccnc(n3)Nc4ccc(c(c4)COC/C=C/COC2)OCCN5CCCC5,HWXVIOGONBBTBY-ONEGZZNKSA-N
110,Ipatasertib,,3.0,Hoffmann-La Roche,0RF,['4ekl'],1.0,0,457.2,3.1,81.6,6,2,6,,"['AKT1', 'AKT2', 'AKT3']",['AGC'],,,Single Stereoisomer,"['GDC-0068', 'Ipatasertib', 'RG-7440']",,,C[C@@H]1C[C@H](c2c1c(ncn2)N3CCN(CC3)C(=O)[C@H](CNC(C)C)c4ccc(cc4)Cl)O,GRZXWCHAXNAUHY-NSISKUIASA-N
111,Filgotinib,,3.0,Galapagos,2HB,"['4p7e', '5ut5']",1.0,0,425.2,2.0,96.7,7,1,5,,['JAK1'],['Tyr'],,,Achiral Molecule,"['G-146034', 'GLPG-0634', 'Filgotinib']",,,c1cc(n2c(c1)nc(n2)NC(=O)C3CC3)c4ccc(cc4)CN5CCS(=O)(=O)CC5,RIJLVEAXPNLDTC-UHFFFAOYSA-N
112,Losmapimod,,3.0,GlaxoSmithKline,,,,0,383.2,3.9,71.1,3,2,5,,"['MAPK14', 'MAPK11', 'MAPK13', 'MAPK12']",['CMGC'],,,Achiral Molecule,"['GSKAHAB', 'GW856553', 'GW856553X', 'Losmapimod']",,,Cc1c(cc(cc1F)C(=O)NC2CC2)c3ccc(cn3)C(=O)NCC(C)(C)C,KKYABQBFGDZVNQ-UHFFFAOYSA-N
113,Abivertinib,,3.0,ACEA Biosciences,,,,0,487.2,4.5,98.4,7,3,7,"AC0010 is an orally active, irreversible EGFR inhibitor that selectively targets mutated EGFRs, and was designed to overcome T790M-induced resistance  in tumours [ 2 ]. It may also inhibit BTK, thus offering extended clinical utility [ 3 ]. We show the structure for the free base form of the compound.",,,,,,"['AC0010', 'Avitinib']",,,CN1CCN(CC1)c2ccc(cc2F)Nc3nc4c(cc[nH]4)c(n3)Oc5cccc(c5)NC(=O)C=C,UOFYSRZSLXWIQB-UHFFFAOYSA-N
114,Nazartinib,,3.0,Novartis,,,,0,494.2,4.3,83.4,6,1,6,,,,,,,['NAZARTINIB'],,,Cc1cc(ccn1)C(=O)Nc2nc3cccc(c3n2[C@@H]4CCCCN(C4)C(=O)/C=C/CN(C)C)Cl,IOMMMLWIABWRKL-WUTDNEBXSA-N
115,Naquotinib,,3.0,Astellas Pharma,8RC,['5y9t'],,1,562.3,2.3,120.2,9,2,9,,['EGFR'],['Tyr'],,,Single Stereoisomer,"['Naquotinib', 'ASP8273']",,,CCc1c(nc(c(n1)C(=O)N)Nc2ccc(cc2)N3CCC(CC3)N4CCN(CC4)C)O[C@@H]5CCN(C5)C(=O)C=C,QKDCLUARMDUUKN-XMMPIXPASA-N
116,Motesanib,,3.0,Amgen,706,['3efl'],2.0,0,373.2,4.0,78.9,5,3,5,,"['FLT1', 'KDR', 'FLT4', 'PDGFRA', 'PDGFRB', 'KIT', 'RET']",['Tyr'],,,Achiral Molecule,"['AMG-706', 'Motesanib']",,,CC1(CNc2c1ccc(c2)NC(=O)c3cccnc3NCc4ccncc4)C,RAHBGWKEPAQNFF-UHFFFAOYSA-N
117,Momelotinib,,3.0,Ym Biosciences Australia,C87,['6fdz'],,0,414.2,3.0,103.2,7,2,6,,"['JAK1', 'JAK2', 'JAK3']",['Tyr'],,,Achiral Molecule,"['CYT-11387', 'GS-0387', 'Momelotinib', 'CYT-387']",,,c1cc(ccc1c2ccnc(n2)Nc3ccc(cc3)N4CCOCC4)C(=O)NCC#N,ZVHNDZWQTBEVRY-UHFFFAOYSA-N
118,Orantinib,,3.0,Pfizer,SU6,"['4jlc', '5yvc']",1.0,0,310.1,3.1,82.2,2,3,4,,"['KDR', 'PDGFRB', 'FGFR1']",['Tyr'],,,Achiral Molecule,"['TSU-68', 'SU-6668', 'Orantinib']",,,Cc1c(c([nH]c1/C=C\2/c3ccccc3NC2=O)C)CCC(=O)O,NHFDRBXTEDBWCZ-ZROIWOOFSA-N
119,Alvocidib,,3.0,Sanofi,CPB,"['1c8k', '1e1y', '3blr', '3ebp', '4o71']",,0,401.1,3.3,94.1,6,3,2,"Investigated for use/treatment in esophageal cancer, leukemia (lymphoid), lung cancer, liver cancer, and lymphoma (unspecified).",,,,,Single Stereoisomer,"['L-86-8275', 'Flavopiridol', 'MDL-107826A', 'HL-275', 'HMR-1275', 'Alvocidib', 'NSC-649890', 'L-868275']",,,CN1CC[C@@H]([C@@H](C1)O)c2c(cc(c3c2oc(cc3=O)c4ccccc4Cl)O)O,BIIVYFLTOXDAOV-YVEFUNNKSA-N
120,Itacitinib,,3.0,Incyte Corporation,,,,1,553.2,3.6,119.6,8,1,5,,['JAK1'],['Tyr'],,,Achiral Molecule,"['INCB-039110', 'INCB-39110', 'Itacitinib', 'INCB039110']",,,c1cnc-2[nH]cnc(c12)c3cnn(c3)C4(CN(C4)C5CCN(CC5)C(=O)c6ccnc(c6F)C(F)(F)F)CC#N,KTBSXLIQKWEBRB-UHFFFAOYSA-N
121,Pyrotinib,,3.0,Hengrui Therapeutics,,,,2,582.2,6.5,112.4,8,2,10,,"['EGFR', 'ERBB2']",['Tyr'],,,Single Stereoisomer,['SHR1258'],,,CCOc1cc2c(cc1NC(=O)/C=C/[C@H]3CCCN3C)c(c(cn2)C#N)Nc4ccc(c(c4)Cl)OCc5ccccn5,SADXACCFNXBCFY-IYNHSRRRSA-N
122,Capmatinib,,3.0,Novartis,,,,0,412.1,3.4,85.1,6,1,4,,['MET'],['Tyr'],,,Achiral Molecule,"['INC280', 'Capmatinib', 'INCB-28060', 'NVP-INC280', 'NYP-INC280-NX', 'INC-280']",,,CNC(=O)c1ccc(cc1F)c2cnc3ncc(n3n2)Cc4ccc5c(c4)cccn5,LIOLIMKSCNQPLV-UHFFFAOYSA-N
123,Selumetinib,,3.0,Astrazeneca,3EW,['4u7z'],3.0,0,456.0,3.5,88.4,6,3,6,,"['MAP2K1', 'MAP2K2']",['STE'],,,Achiral Molecule,"['ARRY-142886', 'AZD-6244', 'ARRY-886', 'Selumetinib']",,,Cn1cnc2c1cc(c(c2F)Nc3ccc(cc3Cl)Br)C(=O)NOCCO,CYOHGALHFOKKQC-UHFFFAOYSA-N
124,Savolitinib,,3.0,Astrazeneca,V0L,"['5lbw', '6sde']",,0,345.1,1.9,91.6,9,0,3,,['MET'],['Tyr'],,,Single Stereoisomer,"['AZD-6094', 'Savolitinib', 'HMPL-504', 'AZD6094']",,,C[C@@H](c1ccc2nccn2c1)n3c4c(ncc(n4)c5cnn(c5)C)nn3,XYDNMOZJKOGZLS-NSHDSACASA-N
125,Saracatinib,,3.0,Astrazeneca,H8H,"['2h8h', '4qmx', '5vcx', '5vd3']",1.0,1,541.2,3.9,90.4,10,1,8,,"['SRC', 'ABL1']",['Tyr'],,,Achiral Molecule,"['AZD-0530', 'Saracatinib', 'AZ-10353926']",,,CN1CCN(CC1)CCOc2cc3c(c(c2)OC4CCOCC4)c(ncn3)Nc5c(ccc6c5OCO6)Cl,OUKYUETWWIPKQR-UHFFFAOYSA-N
126,Avapritinib,,3.0,Blueprint Medicines,,,,0,498.2,2.6,106.3,10,1,5,,,,,,,['BLU-285'],,,C[C@](c1ccc(cc1)F)(c2cnc(nc2)N3CCN(CC3)c4c5cc(cn5ncn4)c6cnn(c6)C)N,DWYRIWUZIJHQKQ-SANMLTNESA-N
127,Ruboxistaurin,['Arxxant'],3.0,Eli Lilly,LY4,"['1uu3', '2j2i']",,0,468.2,3.5,68.5,6,1,2,,,,,,Single Stereoisomer,"['Arxxant', 'LY-333531', 'Ruboxistaurin']",,,CN(C)C[C@@H]1CCn2cc(c3c2cccc3)C4=C(c5cn(c6c5cccc6)CCO1)C(=O)NC4=O,ZCBUQCWBWNUWSU-SFHVURJKSA-N
128,Semaxanib,,3.0,Sugen,X2M,['2x2m'],1.0,0,238.1,3.1,44.9,1,2,1,Investigated for use/treatment in colorectal cancer and lung cancer.,['KDR'],['Tyr'],,,Achiral Molecule,"['SU-5416', 'Semaxinib', 'Semaxanib']",,,Cc1cc([nH]c1/C=C\2/c3ccccc3NC2=O)C,WUWDLXZGHZSWQZ-WQLSENKSSA-N
129,Asciminib,,3.0,Novartis,AY7,['5mo4'],,0,449.1,3.5,103.4,6,3,6,,,,,,,['ASCIMINIB'],,,c1cc(ccc1NC(=O)c2cc(c(nc2)N3CC[C@H](C3)O)c4ccn[nH]4)OC(F)(F)Cl,VOVZXURTCKPRDQ-CQSZACIVSA-N
130,Rigosertib,,3.0,Onconova Therapeutics,6FS,"['5j18', '5j2r', '5ov7']",3.0,0,451.1,2.8,120.4,8,2,11,,"['PIK3CA', 'PLK1']","['Atypical', 'Other']",,,Achiral Molecule,"['Rigosertib', 'ON-01910']",,,COc1ccc(cc1NCC(=O)O)CS(=O)(=O)/C=C/c2c(cc(cc2OC)OC)OC,OWBFCJROIKNMGD-BQYQJAHWSA-N
131,Radotinib,,3.0,Il-Yang Pharmaceutical,,,,2,530.2,5.8,110.5,8,2,6,"Radotinib is indicated for the treatment of different types of cancer, most notably Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (C ML) with resistance or intolerance of other Bcr-Abl tyrosine-kinase inhibitors, such as patients resistant or intolerant to imatinib.","['ABL1', 'PDGFRB']",['Tyr'],,,,"['SUPEC', 'IY5511HCL']",,,Cc1ccc(cc1Nc2nccc(n2)c3cnccn3)C(=O)Nc4cc(cc(c4)n5cc(nc5)C)C(F)(F)F,DUPWHXBITIZIKZ-UHFFFAOYSA-N
132,Quizartinib,,3.0,Ambit Biosciences,P30,"['4rt7', '4xuf']",2.0,2,560.2,5.9,106.2,9,2,7,,"['FLT3', 'CSF1R', 'KIT']",['Tyr'],,,Achiral Molecule,"['ASP-2689', 'AC220', 'Quizartinib', 'AC010220', 'AC-220']",,,CC(C)(C)c1cc(no1)NC(=O)Nc2ccc(cc2)c3cn4c5ccc(cc5sc4n3)OCCN6CCOCC6,CVWXJKQAOSCOAB-UHFFFAOYSA-N
133,Ripretinib,,3.0,Deciphera Pharmaceuticals,,,,2,509.1,5.7,88.0,5,3,5,"Ripretinib (DCC-2618) is an orally bioavailable, potent pan-KIT and PDGFRα kinase inhibitor being developed by Dicephera Pharmaceuticals.  It is  in clinical development for the treatment of  malignancies that are driven by KIT and/or PDGFRα, for example gastrointestinal stromal tumors, glioblastoma multiforme and systemic mastocytosis. Ripretinib has activity across a broad range of resistance mutations in its target kinases, that emerge in response to imatinib treatment. Ripretinib binds to the 'switch pocket' of KIT, a domain that regulates the enzyme's catalytic conformation. Compounds that act in this way are often referred to as switch control inhibitors.",,,,,,"['DCC-2618', 'RIPRETINIB']",,,CCn1c2cc(ncc2cc(c1=O)c3cc(c(cc3Br)F)NC(=O)Nc4ccccc4)NC,CEFJVGZHQAGLHS-UHFFFAOYSA-N
134,Famitinib,,3.0,Jiangsu Hengrui Medicine,,,,0,410.2,3.3,68.4,3,2,6,,"['KIT', 'KDR', 'FLT4', 'PDGFRA', 'PDGFRB', 'FLT1', 'FLT3']",['Tyr'],,,,['SHR-1020'],,,CCN(CC)CCN1CCc2c(c(c([nH]2)/C=C\3/c4cc(ccc4NC3=O)F)C)C1=O,GKEYKDOLBLYGRB-LGMDPLHJSA-N
135,Lestaurtinib,,3.0,Cephalon,,,,0,439.2,3.5,88.7,6,3,1,,['FLT3'],['Tyr'],,,Single Stereoisomer,"['KT-5555', 'KT-555', 'Lestaurtinib', 'SPM-924', 'SP-924', 'A-154475', 'CEP-701', 'Cep-701', 'SP924', 'A-1544750']",,,C[C@@]12[C@](C[C@@H](O1)n3c4ccccc4c5c3c6n2c7ccccc7c6c8c5C(=O)NC8)(CO)O,UIARLYUEJFELEN-LROUJFHJSA-N
136,Rociletinib,,3.0,Clovis Oncology,8JC,"['5xdk', '5xdl']",1.0,1,555.2,4.8,111.7,8,3,8,,['EGFR'],['Tyr'],,,Achiral Molecule,"['CNX-419', 'AVL-301', 'CO-1686', 'Rociletinib']",,,CC(=O)N1CCN(CC1)c2ccc(c(c2)OC)Nc3ncc(c(n3)Nc4cccc(c4)NC(=O)C=C)C(F)(F)F,HUFOZJXAKZVRNJ-UHFFFAOYSA-N
137,Simotinib,,3.0,Advenchen Laboratories,,,,1,500.2,4.4,78.0,8,1,7,,['EGFR'],['Tyr'],,,,['SIM-6802'],,,COc1cc2c(cc1OCCN3CC4(CC4)C5(C3)OCCO5)c(ncn2)Nc6ccc(c(c6)Cl)F,OXWUWXCJDBRCCG-UHFFFAOYSA-N
138,Alisertib,,3.0,Millennium Pharmaceuticals,A5B,['5ia0'],1.0,2,518.1,5.7,105.9,7,2,6,For the treatment of various forms of cancer.,['AURKA'],['Other'],,,Achiral Molecule,"['MLN-8237', 'Alisertib']",,,COc1cccc(c1C2=NCc3cnc(nc3-c4c2cc(cc4)Cl)Nc5ccc(c(c5)OC)C(=O)O)F,ZLHFILGSQDJULK-UHFFFAOYSA-N
139,Cediranib,['Recentin'],3.0,Astrazeneca,,,,1,450.2,5.2,72.5,6,1,8,"For the treatment of liver cancer, advanced non-small cell lung cancer (NSCLC), advanced colorectal cancer (CRC) and other solid tumors.",['KDR'],['Tyr'],,,Achiral Molecule,"['Recentin', 'ZD-2171', 'AZD-2171', 'Cediranib']",,,Cc1cc2c([nH]1)ccc(c2F)Oc3c4cc(c(cc4ncn3)OCCCN5CCCC5)OC,XXJWYDDUDKYVKI-UHFFFAOYSA-N
140,Buparlisib,,3.0,Novartis,SD5,"['3sd5', '5m7e']",1.0,0,410.2,1.8,89.6,8,1,3,,['PIK3CA'],['Atypical'],,,Achiral Molecule,"['NVP-BKM120', 'BKM-120', 'Buparlisib', 'BKM120-NX']",,,c1c(c(cnc1N)c2cc(nc(n2)N3CCOCC3)N4CCOCC4)C(F)(F)F,CWHUFRVAEUJCEF-UHFFFAOYSA-N
141,Tivantinib,,3.0,Daiichi Sankyo,TIV,['5cb4'],,0,369.1,3.6,66.9,3,2,2,,['MET'],['Tyr'],,,Single Stereoisomer,"['ARQ-197', 'Tivantinib']",,,c1ccc2c(c1)c(c[nH]2)[C@H]3[C@@H](C(=O)NC3=O)c4cn5c6c4cccc6CCC5,UCEQXRCJXIVODC-PMACEKPBSA-N
142,Brivanib,,3.0,Bristol Myers Squibb,,,,0,370.1,3.5,84.7,6,2,5,,['KDR'],['Tyr'],,,Single Stereoisomer,"['Brivanib', 'BMS-540215']",,,Cc1cc2c([nH]1)ccc(c2F)Oc3c4c(c(cn4ncn3)OC[C@@H](C)O)C,WCWUXEGQKLTGDX-LLVKDONJSA-N
143,Fruquintinib,,3.0,Hutchison MediPharma,,,,0,393.1,3.9,95.7,7,1,5,,"['FLT1', 'KDR', 'FLT4']",['Tyr'],,,Single Stereoisomer,"['HMP-013', 'HMPL-013']",,,Cc1c(c2ccc(cc2o1)Oc3c4cc(c(cc4ncn3)OC)OC)C(=O)NC,BALLNEJQLSTPIO-UHFFFAOYSA-N
144,Barasertib,,3.0,Astrazeneca,,,,1,587.2,3.6,174.8,9,5,15,,['AURKB'],['Other'],,,Achiral Molecule,"['Barasertib', 'AZD-1152']",,,CCN(CCCOc1ccc2c(c1)ncnc2Nc3cc(n[nH]3)CC(=O)Nc4cccc(c4)F)CCOP(=O)(O)O,GBJVVSCPOBPEIT-UHFFFAOYSA-N
145,Dovitinib,,3.0,Novartis,38O,"['4tyi', '5a46', '5am6', '5am7', '5owq']",1.0,0,392.2,2.5,94.0,5,3,2,,"['FGFR3', 'VEGFA', 'FGFR1', 'PDGFRA', 'KIT', 'CSF1R']","['(*)', 'Tyr']",,,Achiral Molecule,"['GFKI-258', 'TKI-258', 'CHIR-258', 'NVP-TKI258', 'Dovitinib']",,,CN1CCN(CC1)c2ccc3c(c2)[nH]c(n3)c4c(c5c(cccc5F)[nH]c4=O)N,PIQCTGMSNWUMAF-UHFFFAOYSA-N
146,Volasertib,,3.0,Boehringer Ingelheim,IBI,"['3fc2', '5v67', '5vbr']",1.0,1,618.4,4.3,106.2,9,2,10,,['PLK1'],['Other'],,,Single Stereoisomer,"['BI-6727', 'Volasertib']",,,CC[C@H]1N(c2nc(ncc2N(C1=O)C)Nc3c(cc(cc3)C(=O)N[C@H]4CC[C@@H](CC4)N5CCN(CC5)CC6CC6)OC)C(C)C,SXNJFOWDRLKDSF-STROYTFGSA-N
147,Ensartinib,,3.0,Xcovery,,,,1,560.2,4.7,122.5,7,3,6,,['ALK'],['Tyr'],,,,"['X-396', 'X396', 'X-396', 'CAPSULES', 'ENSARTINIB']",,,C[C@@H]1CN(C[C@@H](N1)C)C(=O)c2ccc(cc2)NC(=O)c3cc(c(nn3)N)O[C@H](C)c4c(ccc(c4Cl)F)Cl,GLYMPHUVMRFTFV-QLFBSQMISA-N
148,Dinaciclib,,3.0,Schering-Plough,,,,0,396.2,2.3,92.6,7,2,7,,"['CDK4', 'CDK6', 'BRDT']","['(*)', 'CMGC']",,,Single Stereoisomer,"['MK-7965', 'SCH-727965', 'Dinaciclib']",,,CCc1cnn2c1nc(cc2NCc3ccc[n+](c3)[O-])N4CCCC[C@H]4CCO,PIMQWRZWLQKKBJ-SFHVURJKSA-N
149,Peficitinib,,3.0,Astellas Pharma,9T6,"['6aah', '6aaj', '6aak', '6aam']",,0,326.2,2.0,104.0,4,4,3,,"['JAK1', 'JAK2', 'JAK3', 'TYK2']",['Tyr'],,,Racemic Mixture,"['ASP015K', 'ASP015K', 'hydrobromide']",,,c1c[nH]c2c1c(c(cn2)C(=O)N)N[C@@H]3[C@@H]4C[C@@H]5C[C@H]3C[C@@](C5)(C4)O,DREIJXJRTLTGJC-ZKVNVPQCSA-N
150,Taselisib,,3.0,Hoffmann-La Roche,799,['5t8f'],1.0,0,460.2,3.2,118.7,9,1,5,,"['PIK3CA', 'PIK3CD', 'PIK3CG']",['Atypical'],,,Racemic Mixture,"['RG-7604', 'Taselisib', 'GDC-0032']",,,Cc1nc(n(n1)C(C)C)c2cn3c(n2)-c4ccc(cc4OCC3)c5cnn(c5)C(C)(C)C(=O)N,BEUQXVWXFDOSAQ-UHFFFAOYSA-N
151,Vatalanib,,3.0,Novartis,,,,1,346.1,5.0,50.7,4,1,4,Used in combination with first- and second-line chemotherapy for the treatment of metastatic colorectal cancer and non-small cell lung cancer (NSCLC).,"['FLT1', 'KDR', 'FLT4']",['Tyr'],,,Achiral Molecule,"['BAY-86-5127', 'PTK-787', 'NVP-PTK787', 'ZK-222584', 'K-222584', 'CGP-79787', 'PTK787', 'Vatalanib']",,,c1ccc2c(c1)c(nnc2Nc3ccc(cc3)Cl)Cc4ccncc4,YCOYDOIWSSHVCK-UHFFFAOYSA-N
152,Canertinib,,3.0,Pfizer,,,,0,485.2,4.4,88.6,7,2,9,Investigated for use/treatment in breast cancer and lung cancer.,['EGFR'],['Tyr'],,,Achiral Molecule,"['CI-1033', 'Canertinib']",,,C=CC(=O)Nc1cc2c(cc1OCCCN3CCOCC3)ncnc2Nc4ccc(c(c4)Cl)F,OMZCMEYTWSXEPZ-UHFFFAOYSA-N
153,Masitinib,"['Kinavet', 'Masivet']",3.0,AB Science,G65,['5mql'],,1,498.2,5.3,73.4,7,2,7,,"['KIT', 'PDGFRA', 'PDGFRB', 'FGFR1', 'FGFR2', 'FGFR3']",['Tyr'],,,Achiral Molecule,"['Masivet;Kinavet', 'Masitinib', 'AB-1010']",,,Cc1ccc(cc1Nc2nc(cs2)c3cccnc3)NC(=O)c4ccc(cc4)CN5CCN(CC5)C,WJEOLQLKVOPQFV-UHFFFAOYSA-N
154,Enzastaurin,,3.0,Eli Lilly,,,,1,515.2,4.9,72.2,6,1,5,,,,,,Achiral Molecule,"['LY-317615', 'Enzastaurin']",,,Cn1cc(c2c1cccc2)C3=C(C(=O)NC3=O)c4cn(c5c4cccc5)C6CCN(CC6)Cc7ccccn7,AXRCEOKUDYDWLF-UHFFFAOYSA-N
155,Umbralisib,,3.0,TG Therapeutics,,,,2,571.2,6.7,109.1,8,1,6,,,,,,Single Stereoisomer,"['Umbralisib', 'TGR-1202', 'base', 'RP-5264']",,,C[C@@H](c1c(c(=O)c2cc(ccc2o1)F)c3cccc(c3)F)n4c5c(c(n4)c6ccc(c(c6)F)OC(C)C)c(ncn5)N,IUVCFHHAEHNCFT-INIZCTEOSA-N
156,Crenolanib,,3.0,Arog Pharmaceuticals,6T2,"['5lby', '6bqp']",1.0,0,443.2,3.9,78.4,7,1,5,,"['FLT3', 'PDGFRA', 'PDGFRB']",['Tyr'],,,Achiral Molecule,"['CP-868596', 'ARO-002', 'Crenolanib']",,,CC1(COC1)COc2ccc3c(c2)ncn3c4ccc5cccc(c5n4)N6CCC(CC6)N,DYNHJHQFHQTFTP-UHFFFAOYSA-N
157,Sitravatinib,,3.0,Mirati Therapeutics,,,,2,629.2,6.5,114.5,8,3,12,,"['RET', 'DDR2', 'NTRK1', 'NTRK2', 'NTRK3']",['Tyr'],,,Achiral Molecule,"['MGCD516', 'Sitravatinib']",,,COCCNCc1ccc(nc1)c2cc3c(s2)c(ccn3)Oc4ccc(cc4F)NC(=O)C5(CC5)C(=O)Nc6ccc(cc6)F,WLAVZAAODLTUSW-UHFFFAOYSA-N
158,Crizotinib,['Xalkori'],4.0,Pfizer,VGH,"['2wgj', '2xp2', '2yfx', '3zbf', '4anq', '4ans', '4c9w', '5aaa', '5aab', '5aac', '6imz']",1.0,1,449.1,5.0,78.0,6,2,5,Crizotinib is used for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) that is anaplastic-lymphoma kinase (ALK)-pos itive as detected by a FDA-approved test.,"['ALK', 'MET']",['Tyr'],2011,US-7230098-B2,Single Stereoisomer,"['Xalkori', 'Crizotinib', 'PF-2341066']",Y,,C[C@H](c1c(ccc(c1Cl)F)Cl)Oc2cc(cnc2N)c3cnn(c3)C4CCNCC4,KTEIFNKAUNYNJU-GFCCVEGCSA-N
159,Copanlisib,['Aliqopa'],4.0,Bayer,6E2,['5g2n'],1.0,1,480.2,0.7,139.8,11,2,7,Indicated for the treatment of adult patients with relapsed follicular lymphoma (FL) who have received at least two prior systemic therapies.,"['PIK3CA', 'PIK3CB']",['Atypical'],2017,US-7511041-B2,Achiral Molecule,"['Copanlisib', 'BAY', '80-6946', 'BAY-80-6946']",Y,,COc1c(ccc2c1N=C(N3C2=NCC3)NC(=O)c4cnc(nc4)N)OCCCN5CCOCC5,PZBCKZWLPGJMAO-UHFFFAOYSA-N
160,Cobimetinib,['Cotellic'],4.0,Hoffmann-La Roche,EUI,"['4an2', '4lmn']",3.0,1,531.1,3.8,64.6,4,3,4,"For the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation. Cobimetinib is used in combination with ve murafenib, a BRAF inhibitor.",['MAP2K1'],['STE'],2015,US-7803839-B2,Single Stereoisomer,"['Cotellic', 'RG-7421', 'GDC-0973', 'RG-7420', 'XL-518', 'Cobimetinib']",Y,,c1c(cc(c(c1)Nc2c(c(ccc2C(=O)N3C[C@@](C3)(O)[C@H]4NCCCC4)F)F)F)I,BSMCAPRUBJMWDF-KRWDZBQOSA-N
161,Gefitinib,['Iressa'],4.0,Astrazeneca,IRE,"['2ito', '2ity', '2itz', '3ug2', '4i22', '4wkq', '5y7z', '5y80']",1.5,0,446.2,4.3,68.7,7,1,8,For the continued treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of either platinum-based or docet axel chemotherapies.,['EGFR'],['Tyr'],2003,US-5770599-A,Achiral Molecule,"['Iressa', 'Gefitinib', 'Iressa', 'ZD-1839']",Y,,COc1cc2c(cc1OCCCN3CCOCC3)c(ncn2)Nc4ccc(c(c4)Cl)F,XGALLCVXEZPNRQ-UHFFFAOYSA-N
162,Ibrutinib,['Imbruvica'],4.0,Pharmacyclics,1E8,"['4ifg', '4rz7', '5p9i', '5yu9']",1.5,0,440.2,4.2,99.2,7,1,5,"Ibrutinib was approved by the FDA for the treatment of mantle cell lymphoma, and later in February 2014 for the treatment of chronic lymphocytic leuke mia",['BTK'],['Tyr'],2013,US-7514444-B2,Single Stereoisomer,"['Imbruvica', 'PCI-32765', 'PCI-32765-00', 'Ibrutinib', 'CRA-032765']",Y,149-158,C=CC(=O)N1CCC[C@H](C1)n2c3c(c(n2)c4ccc(cc4)Oc5ccccc5)c(ncn3)N,XYFPWWZEPKGCCK-GOSISDBHSA-N
163,Cabozantinib,"['Cabometyx', 'Cometriq']",4.0,Exelixis,,,2.0,2,501.2,5.5,98.8,6,2,8,For the treatment of metastatic medullary thyroid cancer and for the treatment of patients with advanced renal cell carcinoma (RCC) who have received  prior anti-angiogenic therapy.,"['MET', 'KDR', 'RET']",['Tyr'],2012,US-7579473-B2,Achiral Molecule,"['Cabometyx;Cometriq', 'XL-184', 'Cabozantinib', 'BMS-907351']",Y,,COc1cc2c(ccnc2cc1OC)Oc3ccc(cc3)NC(=O)C4(CC4)C(=O)Nc5ccc(cc5)F,ONIQOQHATWINJY-UHFFFAOYSA-N
164,Pazopanib,['Votrient'],4.0,GlaxoSmithKline,,,1.0,0,437.2,3.1,119.0,8,2,5,Treatment of advanced renal cell cancer and advanced soft tissue sarcoma (in patients previously treated with chemotherapy),"['FLT1', 'KDR', 'FLT4', 'PDGFRA', 'PDGFRB', 'KIT', 'FGFR3', 'ITK', 'FGFR1']",['Tyr'],2009,US-7105530-B2,Achiral Molecule,"['Votrient', 'Pazopanib', 'GW786034']",Y,,Cc1ccc(cc1S(=O)(=O)N)Nc2nccc(n2)N(C)c3ccc4c(n(nc4c3)C)C,CUIHSIWYWATEQL-UHFFFAOYSA-N
165,Neratinib,['Nerlynx'],4.0,Puma Biotechnology,,,,2,556.2,5.9,112.4,8,2,11,"For use as an extended adjuvant treatment in adult patients with early stage HER2-overexpressed/amplified breast cancer, to follow adjuvant trastuzuma b-based therapy","['ERBB2', 'EGFR']",['Tyr'],2017,US-6288082-B1,Achiral Molecule,"['WAY-179272', 'CDP-820', 'Neratinib', 'HKI-272']",Y,,CCOc1cc2c(cc1NC(=O)/C=C/CN(C)C)c(c(cn2)C#N)Nc3ccc(c(c3)Cl)OCc4ccccn4,JWNPDZNEKVCWMY-VQHVLOKHSA-N
166,Netarsudil,['Rhopressa'],4.0,Aerie Pharmaceutical,,,,0,453.2,4.9,94.3,5,2,7,"On december 18, 2017, the FDA approved netarsudil to treat glaucoma or ocular hypertension",,,2017,,Racemic Mixture,['AR-13324'],Y,,Cc1ccc(c(c1)C)C(=O)OCc2ccc(cc2)[C@@H](CN)C(=O)Nc3ccc4cnccc4c3,OURRXQUGYQRVML-AREMUKBSSA-N
167,Nilotinib,['Tasigna'],4.0,Novartis,NIL,"['3cs9', '3gp0', '5mo4']",2.0,2,529.2,6.4,97.6,7,2,6,"For the potential treatment of various leukemias, including chronic myeloid leukemia (CML).","['ABL1', 'KIT']",['Tyr'],2007,US-7169791-B2,Achiral Molecule,"['Tasigna', 'Nilotinib', 'AMN-107']",Y,,Cc1ccc(cc1Nc2nccc(n2)c3cccnc3)C(=O)Nc4cc(cc(c4)n5cc(nc5)C)C(F)(F)F,HHZIURLSWUIHRB-UHFFFAOYSA-N
168,Dabrafenib,['Tafinlar'],4.0,GlaxoSmithKline,P06,"['4xv2', '5csw', '5hie']",1.5,2,519.1,5.4,110.9,7,2,5,Dabrafenib is indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved  test.,"['BRAF', 'RAF1', 'SIK1', 'NEK11', 'LIMK1']","['NEK', 'TKL', 'CAMK']",2013,US-7994185-B2,Achiral Molecule,"['Tafinlar', 'GSK2118436A', 'Dabrafenib']",Y,,CC(C)(C)c1nc(c(s1)c2ccnc(n2)N)c3cccc(c3F)NS(=O)(=O)c4c(cccc4F)F,BFSMGDJOXZAERB-UHFFFAOYSA-N
169,Dasatinib,['Sprycel'],4.0,Bristol Myers Squibb,1N1,"['2gqg', '2y6o', '2zva', '3g5d', '3k54', '3lfa', '3oct', '3oht', '3qlg', '3sxr', '4qms', '4xey', '4xli', '5bvw', '5h2u', '5i9y', '5owr', '5vcv', '6bsd', '6fnm']",1.0,0,487.2,3.3,106.5,9,3,7,"For the treatment of adults with chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia with resistance or intolerance to p rior therapy. Also indicated for the treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to prior therapy.","['ABL1', 'SRC', 'EPHA2', 'LCK', 'YES1', 'KIT', 'PDGFRB', 'ABL2', 'FYN']",['Tyr'],2006,US-6596746-B1,Achiral Molecule,"['Sprycel;Dasatinib', 'BMS-354825-03', 'BMS-354825', 'Dasatinib']",Y,280-286,Cc1cccc(c1NC(=O)c2cnc(s2)Nc3cc(nc(n3)C)N4CCN(CC4)CCO)Cl,ZBNZXTGUTAYRHI-UHFFFAOYSA-N
170,Trametinib,['Mekinist'],4.0,GlaxoSmithKline,,,3.0,1,615.1,3.9,107.1,8,2,5,"Trametinib is indicated for the treatment of unresectable or metastatic melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved te st.","['BRAF', 'MAP2K1', 'MAP2K2']","['TKL', 'STE']",2013,US-7378423-B2,Achiral Molecule,"['Mekinist', 'GSK1120212', 'Trametinib']",Y,293-303,Cc1c2c(c(n(c1=O)C)Nc3ccc(cc3F)I)c(=O)n(c(=O)n2c4cccc(c4)NC(=O)C)C5CC5,LIRYPHYGHXZJBZ-UHFFFAOYSA-N
171,Ruxolitinib,['Jakafi'],4.0,Incyte Corporation,RXT,['4u5j'],1.0,0,306.2,3.5,83.2,5,1,4,"Treatment of intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera (post-PV) myelofibrosis and post-essenti al thrombocythemia (post-ET) myelofibrosis. [Lexicomp] Myeolofibrosis is the proliferation of abnormal bone marrow stem cells which cause fibrosis (the excessive formation of connective tissue).","['JAK1', 'JAK2']",['Tyr'],2011,US-7598257-B2,Single Stereoisomer,"['Jakavi', 'INCB-018424', 'Ruxolitinib']",Y,,c1c[nH]c2c1c(ncn2)c3cnn(c3)[C@H](CC#N)C4CCCC4,HFNKQEVNSGCOJV-OAHLLOKOSA-N
172,Vandetanib,"['Caprelsa', 'Zactima']",4.0,Ipr Pharmaceuticals,ZD6,['2ivu'],1.5,1,474.1,5.0,59.5,6,1,6,"Vandetanib is currently approved as an alternative to local therapies for both unresectable and disseminated disease. Because Vandetanib can prolong t he Q-T interval, it is contraindicated for use in patients with serious cardiac complications such as congenital long QT syndrome and uncompensated heart failure.","['VEGFA', 'EGFR', 'PTK6', 'TEK', 'RET']","['(*)', 'Tyr']",2011,US-RE42353-E1,Achiral Molecule,"['Caprelsa;Zactima', 'GNF-Pf-2188', 'ZD-6474', 'Vandetanib', 'ZD-64']",Y,,CN1CCC(CC1)COc2cc3c(cc2OC)c(ncn3)Nc4ccc(cc4F)Br,UHTHHESEBZOYNR-UHFFFAOYSA-N
173,Erlotinib,['Tarceva'],4.0,Osi Pharmaceuticals,AQ4,"['1m17', '4hjo', '6dwn']",1.5,0,393.2,3.4,74.7,7,1,10,"For the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen.  Also for use, in combination with gemcitabine, as the first-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer.","['EGFR', 'NR1I2']","['(*)', 'Tyr']",2004,US-5747498-A,Achiral Molecule,"['Tarceva', 'Erlotinib', 'OSI-774', 'RG-1415', 'CP-358774', 'R-1415', 'Ro-508231']",Y,,COCCOc1cc2c(cc1OCCOC)ncnc2Nc3cccc(c3)C#C,AAKJLRGGTJKAMG-UHFFFAOYSA-N
174,Pexidartinib,['Turalio'],4.0,Daiichi Sankyo,P31,['4r7h'],2.0,1,417.1,5.2,66.5,4,2,5,"On august 2019, FDA approved pexidartinib to treat adult patients with symptomatic tenosynovial giant cell tumor","['FLT3', 'KIT', 'CSF1R']",['Tyr'],2019,,Achiral Molecule,"['CML-261', 'Pexidartinib', 'PLX3397']",Y,,c1cc(ncc1Cc2c[nH]c3c2cc(cn3)Cl)NCc4ccc(nc4)C(F)(F)F,JGWRKYUXBBNENE-UHFFFAOYSA-N
175,Tofacitinib,['Xeljanz'],4.0,Pfizer,MI1,"['3eyg', '3fup', '3lxk', '3lxn', '4oti']",1.0,0,312.2,1.5,88.9,5,1,3,"For the treatment of moderate to severe rheumatoid arthritis which is resistant or intolerant to methotrexate therapy. It may also be used as an adjun ct to methotrexate therapy, or other non-biologic disease-modifying antirheumatic drugs (DMARDS), when methotrexate alone is not sufficient. Tofacitinib has also been investigated as a preventative therapy for kidney transplant rejections, and as a treatment for psoriasis, ulcerative colitis, and ankylosing spondylitis. It is not to be initiated in patients with a history of chronic or recurrent infections, or in the presence of active infection, even if localized, due to reports of serious and sometimes fatal infections (commonly pneumonia, herpes zoster and urinary tract infections). Use of tofacitinib is also discouraged in those who have been, or are likely to be, exposed to TB. An increased likelihood of exposure may be encountered by traveling to certain areas. In addition, tofacitinib is not to be used in patients with severe hepatic impairment, or low hemoglobin (less than 9g/dL). Cautioned is advised when using tofacitinib in patients at risk of gastrointestinal perforation, and in the elderly who are more susceptible to infection.","['JAK1', 'JAK2', 'JAK3', 'TYK2']",['Tyr'],2012,US-6956041-B2,Single Stereoisomer,"['Tasocitinib', '550', 'CP-690550', 'CP-690', 'Tofacitinib']",Y,,C[C@@H]1CCN(C[C@@H]1N(C)c2c3cc[nH]c3ncn2)C(=O)CC#N,UJLAWZDWDVHWOW-YPMHNXCESA-N
176,Nintedanib,"['Ofev', 'Vargatef']",4.0,Boehringer Ingelheim,XIN,"['3c7q', '5maf', '5te0', '6nec']",1.0,1,539.3,3.6,94.2,7,2,7,Nintedanib is indicated for the treatment of idiopathic pulmonary fibrosis (IPF).,"['FLT1', 'KDR', 'FLT4', 'FGFR1', 'FGFR2', 'FGFR3', 'FLT3', 'LCK', 'LYN', 'SRC']",['Tyr'],2014,US-6762180-B1,Achiral Molecule,"['Ofev;Vargatef', 'Nintedanib', 'BIBF-1120']",Y,,CN1CCN(CC1)CC(=O)N(C)c2ccc(cc2)N/C(=C\3/c4ccc(cc4NC3=O)C(=O)OC)/c5ccccc5,XZXHXSATPCNXJR-ZIADKAODSA-N
177,Tivozanib,,4.0,Aveo Pharmaceuticals,AV9,['4ase'],2.0,1,454.1,5.6,107.7,7,2,6,Tivozanib is an oral VEGF receptor tyrosine kinase inhibitor.,"['FLT1', 'KDR', 'FLT4']",['Tyr'],,,Achiral Molecule,"['AV-951', 'Tivozanib', 'Kil-8951', 'Kil8951', 'ASP-4130', 'KRN-951']",N,,Cc1cc(no1)NC(=O)Nc2ccc(cc2Cl)Oc3ccnc4c3cc(c(c4)OC)OC,SPMVMDHWKHCIDT-UHFFFAOYSA-N
178,Larotrectinib,['Vitrakvi'],4.0,Array BioPharma,,,,0,428.2,2.9,86.0,6,2,3,"On november 26, 2018, the FDA approved larotrectinib to treat patients whose cancers have a specific genetic feature (biomarker)","['NTRK1', 'NTRK2', 'NTRK3']",['Tyr'],2018,,Single Stereoisomer,"['Larotrectinib', 'LOXO-101']",Y,,c1cc(c(cc1F)[C@H]2CCCN2c3ccn4c(n3)c(cn4)NC(=O)N5CC[C@@H](C5)O)F,NYNZQNWKBKUAII-KBXCAEBGSA-N
179,Fasudil,,4.0,Asahi Kasei Pharma Corp,M77,"['1q8w', '2esm', '2f2u', '2gni', '3tku', '5lcp', '5nw8', '5o0e', '5ok3', '5vef', '6em2', '6emb', '6ers', '6erw', '6i2a', '6i2c']",,0,291.1,1.2,62.3,4,1,2,Fasudil is a potent inhibitor of the Rho-kinases ROCK1 and ROCK2.,,,,,Achiral Molecule,"['HA-1077', 'Fasudil', 'ZK-258594', 'AT-877']",N,,c1cc2cnccc2c(c1)S(=O)(=O)N3CCCNCC3,NGOGFTYYXHNFQH-UHFFFAOYSA-N
180,Entrectinib,['Rozlytrek'],4.0,Ignyta,YMX,"['5fto', '5kvt']",1.0,2,560.3,5.0,85.5,6,3,7,"On august 2019, FDA approved entrectinib to treat adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive and  to treat adult and pediatric patients 12 years of age and older with solid tumors","['NTRK1', 'NTRK2', 'NTRK3', 'ROS1', 'ALK']",['Tyr'],2019,,Achiral Molecule,"['Entrectinib', 'RXDX-101', 'NMS-E628']",Y,,CN1CCN(CC1)c2ccc(c(c2)NC3CCOCC3)C(=O)Nc4c5cc(ccc5[nH]n4)Cc6cc(cc(c6)F)F,HAYYBYPASCDWEQ-UHFFFAOYSA-N
181,Sunitinib,['Sutent'],4.0,Cp Pharmaceuticals,B49,"['2y7j', '3g0e', '3g0f', '3miy', '3ti1', '4agd', '4ks8', '4qmz', '6nfy', '6nfz', '6ng0']",1.0,0,398.2,3.3,77.2,3,3,7,For the treatment of advanced renal cell carcinoma as well as the treatment of gastrointestinal stromal tumor after disease progression on or intolera nce to imatinib mesylate.,"['PDGFRB', 'FLT1', 'KIT', 'KDR', 'FLT4', 'FLT3', 'CSF1R', 'PDGFRA']",['Tyr'],2006,US-6573293-B2,Achiral Molecule,"['Sutent', 'Sunitinib', 'SU-11248', 'Sutent']",Y,,CCN(CC)CCNC(=O)c1c(c([nH]c1C)/C=C\2/c3cc(ccc3NC2=O)F)C,WINHZLLDWRZWRT-ATVHPVEESA-N
182,Sorafenib,['Nexavar'],4.0,Bayer,BAX,"['1uwh', '1uwj', '3gcs', '3heg', '3rgf', '3wze', '4asd', '5hi2']",2.0,1,464.1,5.5,92.3,4,3,5,Sorafenib is indicated for the treatment of unresectable hepatocellular carcinoma and advanced renal cell carcinoma.,"['BRAF', 'RAF1', 'FLT4', 'KDR', 'FLT3', 'PDGFRB', 'KIT', 'FGFR1', 'RET', 'FLT1']","['TKL', 'Tyr']",2005,US-7235576-B1,Achiral Molecule,"['Nexavar', 'Sorafenib', 'BAY-43-9006']",Y,205.6,CNC(=O)c1cc(ccn1)Oc2ccc(cc2)NC(=O)Nc3ccc(c(c3)C(F)(F)F)Cl,MLDQJTXFUGDVEO-UHFFFAOYSA-N
183,Abemaciclib,['Verzenio'],4.0,Eli Lilly,6ZV,['5l2s'],1.0,1,506.3,4.9,75.0,8,1,7,"On September 28, 2017, the Food and Drug Administration approved abemaciclib (VERZENIO, Eli Lilly and Company) in combination with fulvestrant for wom en with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy. In addition, abemaciclib was approved as monotherapy for  women and men with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting.","['CDK4', 'CDK6']",['CMGC'],2017,US-7855211-B2,Achiral Molecule,"['Verzenio', 'Abemaciclib', 'LY-2835219']",Y,,CCN1CCN(CC1)Cc2ccc(nc2)Nc3ncc(c(n3)c4cc5c(c(c4)F)nc(n5C(C)C)C)F,UZWDCWONPYILKI-UHFFFAOYSA-N
184,Vemurafenib,['Zelboraf'],4.0,Hoffmann-La Roche,032,"['3og7', '4rzv', '5hes']",1.5,1,489.1,5.5,91.9,4,2,7,"Vemurafenib is approved since 2011 for the treatment of metastatic melanoma with a mutation on BRAF in the valine located in the exon 15 at codon 600,  this mutation is denominated as V600E.",['BRAF'],['TKL'],2011,US-7504509-B2,Achiral Molecule,"['Zelboraf', 'Vemurafenib', 'PLX-4032', 'Ro-5185426', 'RG-7204']",Y,272,CCCS(=O)(=O)Nc1ccc(c(c1F)C(=O)c2c[nH]c3c2cc(cn3)c4ccc(cc4)Cl)F,GPXBXXGIAQBQNI-UHFFFAOYSA-N
185,Osimertinib,['Tagrisso'],4.0,Astrazeneca,YY3,['4zau'],1.0,0,499.3,4.5,87.6,8,2,10,"Osimertinib is indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell  lung cancer (NSCLC), as detected by an FDA- approved test, who have progressed on or after EGFR-TKI therapy.",['EGFR'],['Tyr'],2015,US-8946235-B2,Achiral Molecule,"['Tagrisso', 'Osimertinib', 'AZD-9291']",Y,,Cn1cc(c2c1cccc2)c3ccnc(n3)Nc4cc(c(cc4OC)N(C)CCN(C)C)NC(=O)C=C,DUYJMQONPNNFPI-UHFFFAOYSA-N
186,Alpelisib,['Piqray'],4.0,Novartis,1LT,['4jps'],,0,441.1,3.8,101.2,5,2,4,"On may 2019, FDA approved alpelisib to treat breast cancer",['PIK3CA'],['Atypical'],2019,,Single Stereoisomer,"['NVP-BYL719', 'Alpelisib', 'BYL-719']",Y,,Cc1c(sc(n1)NC(=O)N2CCC[C@H]2C(=O)N)c3ccnc(c3)C(C)(C)C(F)(F)F,STUWGJZDJHPWGZ-LBPRGKRZSA-N
187,Lenvatinib,"['Kisplyx', 'Lenvima']",4.0,Eisai,LEV,"['3wzd', '5zv2']",1.5,0,426.1,4.1,115.6,5,3,6,"Lenvatinib is indicated for the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated  thyroid cancer.","['FLT1', 'KDR', 'FLT4', 'FGFR1', 'FGFR2', 'FGFR3', 'FGFR4', 'KIT']",['Tyr'],2015,US-7253286-B2,Achiral Molecule,"['Lenvima;Kisplyx', 'ER-203492-00', 'Lenvatinib']",Y,,COc1cc2c(cc1C(=O)N)c(ccn2)Oc3ccc(c(c3)Cl)NC(=O)NC4CC4,WOSKHXYHFSIKNG-UHFFFAOYSA-N
188,Erdafitinib,['Balversa'],4.0,Janssen,5SF,['5ew8'],1.0,0,446.2,4.2,77.3,8,1,9,"On april 2019, FDA approved erdafitinib to treat adult patients with locally advanced or metastatic bladder cancer",['FGFR1'],['Tyr'],2019,,Achiral Molecule,"['Erdafitinib', 'JNJ-42756493']",Y,,CC(C)NCCN(c1ccc2c(c1)nc(cn2)c3cnn(c3)C)c4cc(cc(c4)OC)OC,OLAHOMJCDNXHFI-UHFFFAOYSA-N
189,Lorlatinib,['Lorbrena'],4.0,Pfizer,5P8,"['4cli', '4clj', '4uxl', '5a9u', '5aa8', '5aa9']",1.0,0,406.2,2.8,110.1,7,1,0,"On november 2, 2018, the FDA approved lorlatinib to treat patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cance r","['ALK', 'ROS1']",['Tyr'],2018,,Single Stereoisomer,"['Lorlatinib', 'PF-06463922']",Y,,C[C@@H]1c2cc(ccc2C(=O)N(Cc3c(c(n(n3)C)C#N)-c4cc(c(nc4)N)O1)C)F,IIXWYSCJSQVBQM-LLVKDONJSA-N
190,Upadacitinib,['Rinvoq'],4.0,Abbvie,,,,0,380.2,2.9,78.3,4,2,3,"On august 2019, FDA approved fedratinib to treat adults with moderately to severely active rheumatoid arthritis",['JAK1'],['Tyr'],2019,,Single Stereoisomer,"['ABT-494', 'Upadacitinib']",Y,,CC[C@@H]1CN(C[C@@H]1c2cnc3n2c4cc[nH]c4nc3)C(=O)NCC(F)(F)F,WYQFJHHDOKWSHR-MNOVXSKESA-N
191,Fedratinib,['Inrebic'],4.0,Sanofi,2TA,"['4ogj', '4ps5']",,1,524.3,4.8,108.5,8,3,10,"On august 2019, FDA approved fedratinib to treat adult patients with intermediate-2 or high-risk primary or secondary myelofibrosis","['JAK2', 'FLT3', 'BRD4']","['(*)', 'Tyr']",2019,,Achiral Molecule,"['SAR-302503', 'Fedratinib', 'TG101348', 'TG-101348']",Y,,Cc1cnc(nc1Nc2cccc(c2)S(=O)(=O)NC(C)(C)C)Nc3ccc(cc3)OCCN4CCCC4,JOOXLOJCABQBSG-UHFFFAOYSA-N
192,Dacomitinib,['Vizimpro'],4.0,Pfizer,1C9,"['4i23', '4i24']",1.0,1,469.2,5.2,79.4,6,2,7,"On october 27, 2018, the FDA approved dacomitinib to treat metastatic non-small-cell lung cancer",['EGFR'],['Tyr'],2018,,Achiral Molecule,"['Dacomitinib', 'PF-00299804']",Y,184-187,COc1cc2c(cc1NC(=O)/C=C/CN3CCCCC3)c(ncn2)Nc4ccc(c(c4)Cl)F,LVXJQMNHJWSHET-AATRIKPKSA-N
193,Binimetinib,['Mektovi'],4.0,Novartis,,,,0,440.0,3.0,88.4,6,3,6,"On June 27, 2018, the Food and Drug Administration approved encorafenib and binimetinib in combination patients with unresectable or metastatic melano ma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.",['MAP2K1'],['STE'],2018,,Achiral Molecule,"['ARRY-162', 'NVP-MEK162', 'Binimetinib', 'MEK-162', 'ARRY-438162']",Y,,Cn1cnc2c1cc(c(c2F)Nc3ccc(cc3F)Br)C(=O)NOCCO,ACWZRVQXLIRSDF-UHFFFAOYSA-N
194,Encorafenib,['Braftovi'],4.0,Novartis,,,,1,539.2,3.9,140.1,9,3,9,"On June 27, 2018, the Food and Drug Administration approved encorafenib and binimetinib in combination patients with unresectable or metastatic melano ma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.",['BRAF'],['TKL'],2018,,Single Stereoisomer,"['NVP-LGX818-NXA', 'LGX-818', 'Encorafenib', 'NVP-LGX818']",Y,,C[C@@H](CNc1nccc(n1)c2cn(nc2c3cc(cc(c3F)NS(=O)(=O)C)Cl)C(C)C)NC(=O)OC,CMJCXYNUCSMDBY-ZDUSSCGKSA-N
195,Zanubrutinib,,4.0,BeiGene,,,,0,471.2,4.2,102.5,6,2,6,"Zanubrutinib (BGB-3111) is a potent, selective and and irreversible BTK inhibitor that is being investigated for clinical utility in the treatment of  hematological cancers, such as non-Hodgkin's lymphoma and chronic lymphocytic leukemia (CLL) [ 1-2 ].",,,2019,,,"['BGB-3111', 'ZANUBRUTINIB']",Y,,C=CC(=O)N1CCC(CC1)C2CCNc3n2nc(c3C(=O)N)c4ccc(cc4)Oc5ccccc5,RNOAOAWBMHREKO-UHFFFAOYSA-N
196,Duvelisib,['Copiktra'],4.0,Infinity Pharmacueticals,,,,0,416.1,4.5,88.5,6,2,4,"On october 27, 2018, the FDA approved duvelisib to treat relapsed or refractory chronic lymphocytic leukemia, small lymphocytic lymphoma and follicula r lymphoma","['PIK3CD', 'PIK3CG']",['Atypical'],2018,,Single Stereoisomer,"['INK-1197', 'INK-1147', 'IPI-145', 'Duvelisib']",Y,>190,C[C@@H](c1cc2cccc(c2c(=O)n1c3ccccc3)Cl)Nc4c5c([nH]cn5)ncn4,SJVQHLPISAIATJ-ZDUSSCGKSA-N
197,Gilteritinib,['Xospata'],4.0,Astellas Pharma,C6F,['6jqr'],,1,552.4,2.7,121.1,10,3,9,"On november 28, 2018, the FDA approved gilteritinib to treat patients who have relapsed or refractory acute myeloid leukemia (AML)","['FLT3', 'AXL', 'ALK']",['Tyr'],2018,,Achiral Molecule,"['ASP-2215', 'Gilteritinib']",Y,,CCc1c(nc(c(n1)C(=O)N)Nc2ccc(c(c2)OC)N3CCC(CC3)N4CCN(CC4)C)NC5CCOCC5,GYQYAJJFPNQOOW-UHFFFAOYSA-N
198,Fostamatinib,['Tavalisse'],4.0,Rigel Pharmaceuticals,2RC,['4o75'],,2,580.1,3.1,186.7,12,4,10,Indicated for the treatment of chronic immune thrombocytopenia (ITP) in adult patients who have had an insufficient response to a previous treatment,['SYK'],['Tyr'],2018,,Achiral Molecule,"['R-935788', 'R-788', 'Free', 'acid', 'R-935788', 'Free', 'acid', 'Fostamatinib', 'R-788']",Y,,CC1(C(=O)N(c2c(ccc(n2)Nc3c(cnc(n3)Nc4cc(c(c(c4)OC)OC)OC)F)O1)COP(=O)(O)O)C,GKDRMWXFWHEQQT-UHFFFAOYSA-N
199,Bosutinib,['Bosulif'],4.0,Wyeth,DB8,"['3soa', '3ue4', '4mxo', '4mxx', '4mxy', '4mxz', '4qmn', '5ajq', '5i9x', '5vc3', '5vcy', '6fdy', '6op9']",1.0,2,529.2,5.2,82.9,8,1,9,"Treatment of chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) with resistance or intoler ance to prior therapy in adult patients.","['BCR', 'ABL1', 'LYN', 'HCK', 'SRC', 'CDK2', 'MAP2K1', 'MAP2K2', 'MAP3K2', 'CAMK2G']","['Atypical', 'Tyr', 'STE', 'CAMK', 'CMGC']",2012,US-6002008-A,Achiral Molecule,"['Bosulif', 'Bosutinib', 'Monohydrate', 'Bosutinib', 'SKI-606']",Y,,CN1CCN(CC1)CCCOc2cc3c(cc2OC)c(c(cn3)C#N)Nc4cc(c(cc4Cl)Cl)OC,UBPYILGKFZZVDX-UHFFFAOYSA-N
200,Alectinib,['Alecensa'],4.0,Hoffmann-La Roche,EMH,"['3aox', '5xv7']",1.0,0,482.3,4.8,72.4,5,1,3,"Alectinib is a kinase inhibitor indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive, metastatic non-small cell lung  cancer (NSCLC) who have progressed on or are intolerant to crizotinib. This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.",['ALK'],['Tyr'],2015,US-9126931-B2,Achiral Molecule,"['Alectinib', 'CH-5424802', 'AF-802']",Y,,CCc1cc2c(cc1N3CCC(CC3)N4CCOCC4)C(c5c(c6ccc(cc6[nH]5)C#N)C2=O)(C)C,KDGFLJKFZUIJMX-UHFFFAOYSA-N
201,Palbociclib,['Ibrance'],4.0,Pfizer,LQQ,"['2euf', '5l2i']",1.0,0,447.2,3.0,105.0,9,2,5,"Palbociclib is indicated in combination with letrozole for the treatment of postmenopausal women with estrogen receptor (ER)-positive, human epidermal  growth factor receptor 2 (HER2)-negative advanced breast cancer as initial endocrine-based therapy for their metastatic disease. This indication is approved under accelerated approval based on progression-free survival (PFS). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.","['CDK4', 'CDK6']",['CMGC'],2015,US-6936612-B2,Achiral Molecule,"['Ibrance', 'Palbociclib', 'PD-0332991']",Y,263-266,Cc1c2cnc(nc2n(c(=O)c1C(=O)C)C3CCCC3)Nc4ccc(cn4)N5CCNCC5,AHJRHEGDXFFMBM-UHFFFAOYSA-N
202,Afatinib,['Gilotrif'],4.0,Boehringer Ingelheim,0WM,['4g5j'],1.0,0,485.2,4.4,88.6,7,2,8,Afatinib is a kinase inhibitor indicated for the first-line treatment of patient with metastatic non-small cell lung cancer (NSCLC) whose tumours have  epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test.,"['EGFR', 'ERBB2', 'ERBB4']",['Tyr'],2013,US-6251912-B1,Single Stereoisomer,"['Giotrif;Gilotrif', 'Afatinib', 'BIBW-2992']",Y,,CN(C)C/C=C/C(=O)Nc1cc2c(cc1O[C@H]3CCOC3)ncnc2Nc4ccc(c(c4)Cl)F,ULXXDDBFHOBEHA-CWDCEQMOSA-N
203,Acalabrutinib,['Calquence'],4.0,Astrazeneca,,,,0,465.2,3.3,118.5,7,2,4,Acalabrutinib is currently indicated for the treatment of adult patients with Mantle Cell Lymphoma (MCL) who have received at least one prior therapy,['BTK'],['Tyr'],2017,US-9290504-B2,Single Stereoisomer,"['Calquence', 'ACP-196', 'Acalabrutinib']",Y,,CC#CC(=O)N1CCC[C@H]1c2nc(c3n2ccnc3N)c4ccc(cc4)C(=O)Nc5ccccn5,WDENQIQQYWYTPO-IBGZPJMESA-N
204,Anlotinib,,4.0,Advenchen Laboratories,,,,0,407.2,4.8,82.4,5,2,6,"Anlotinib (AL3818) is a non-selective inhibitor of multiple receptor tyrosine kinases, including vascular endothelial growth factor receptor type 2 (V EGFR-2, FLT1) and type 3 (VEGFR-3, FLT4). It is being investigated for antineoplastic and anti-angiogenic potential. The dihydrochloride has PubChem CID: 57380530. Preparation and crystallisation of AL3818 is described in patent WO2016179123.","['KDR', 'FLT4']",['Tyr'],,,,"['ALTN', 'APCII', 'AL3818', 'ATC', 'I', 'FU', 'KE', 'WEI', 'APC', 'I', 'ATCII', 'ANLOTINIB']",N,,Cc1cc2c([nH]1)ccc(c2F)Oc3ccnc4c3cc(c(c4)OCC5(CC5)N)OC,KSMZEXLVHXZPEF-UHFFFAOYSA-N
205,Baricitinib,['Olumiant'],4.0,Eli Lilly,3JW,['4w9x'],1.0,0,371.1,1.1,120.6,7,1,5,"Indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intoler ant to one or more disease-modifying anti-rheumatic drugs as monotherapy or in combination with methotrexate.","['JAK1', 'JAK2']",['Tyr'],2017,,Achiral Molecule,"['Baricitinib', 'LY-3009104', 'INCB-28050', 'INCB-028050']",Y,,CCS(=O)(=O)N1CC(C1)(CC#N)n2cc(cn2)c3c4cc[nH]c4ncn3,XUZMWHLSFXCVMG-UHFFFAOYSA-N
206,Axitinib,['Inlyta'],4.0,Pfizer,AXI,"['4ag8', '4agc', '4twp', '4wa9']",2.0,0,386.1,4.6,70.7,4,2,5,Used in kidney cell cancer and investigated for use/treatment in pancreatic and thyroid cancer.,"['FLT1', 'KDR', 'FLT4']",['Tyr'],2012,US-6534524-B1,Achiral Molecule,"['Inlyta', 'AG-13736', 'Axitinib', 'AG-013736']",Y,,CNC(=O)c1ccccc1Sc2ccc3c(c2)[nH]nc3/C=C/c4ccccn4,RITAVMQDGBJQJZ-FMIVXFBMSA-N
207,Brigatinib,['Alunbrig'],4.0,Ariad Pharmaceuticals,6GY,['6mx8'],1.0,2,583.3,5.1,85.9,9,2,8,"The anaplastic lymphoma kinase positive, metastatic non-small cell lung cancer (ALK+ NSCLC), represents only 3-5% of the NSCLC cancer cases, but the A LK mutation, overexpression and presence in several oncogenic fusion proteins in solid and hematologic tumors have pointed out the importance as well as its potential as a cancer therapy target. The ALK-related cases of NSCLC are associated with the presence of the fusion gene EML4-ALK which fused the ALK protein with the echinoderm microtubule-associated protein like-4 whose original function is the correct formation of microtubules. The presence of the aberrant fusion protein results in abnormal signaling that provokes increased cell growth, proliferation and survival. Crizotinib is indicated for the treatment of such cases but the presence of ALK kinase domain mutations confer resistance to the treatment. Thus, brigatinib is indicated for the treatment of patients with ALK+ NSCLC with intolerance to Crizotinib.","['ALK', 'EGFR']",['Tyr'],2017,US-9012462-B2,Achiral Molecule,"['Alunbrig', 'AP-26113', 'Brigatinib']",Y,,CN1CCN(CC1)C2CCN(CC2)c3ccc(c(c3)OC)Nc4ncc(c(n4)Nc5ccccc5P(=O)(C)C)Cl,AILRADAXUVEEIR-UHFFFAOYSA-N
208,Ceritinib,['Zykadia'],4.0,Novartis,4MK,['4mkc'],1.0,2,557.2,6.4,105.2,8,3,9,Ceritinib is a kinase inhibitor indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung  cancer (NSCLC) who have progressed on or are intolerant to crizotinib. This indication is approved under accelerated approval based on tumor response rate and duration of response. An improvement in survival or disease-related symptoms has not been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.,['ALK'],['Tyr'],2014,US-7153964-B2,Achiral Molecule,"['Zykadia', 'Ceritinib', 'NVP-LDK378-NX']",Y,,Cc1cc(c(cc1C2CCNCC2)OC(C)C)Nc3ncc(c(n3)Nc4ccccc4S(=O)(=O)C(C)C)Cl,VERWOWGGCGHDQE-UHFFFAOYSA-N
209,Regorafenib,['Stivarga'],4.0,Bayer,,,2.0,1,482.1,5.7,92.3,4,3,5,"Regorafenib is indicated for the treatment of patients with metastatic colorectal cancer (CRC) who have been previously treated with fluoropyrimidine- , oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if KRAS wild type, an anti-EGFR therapy. Regorafenib is also indicated for the treatment of patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.","['FLT1', 'KDR', 'FLT4', 'KIT', 'PDGFRA', 'PDGFRB', 'FGFR1', 'FGFR2', 'TEK', 'DDR2', 'NTRK1', 'EPHA2', 'RAF1', 'BRAF', 'MAPK11', 'FRK', 'ABL1', 'RET']","['TKL', 'Tyr', 'CMGC']",2012,US-7351834-B1,Achiral Molecule,"['Stivarga', 'Regorafenib', 'BAY-734506', 'monohydrate', 'BAY-73-4506']",Y,,CNC(=O)c1cc(ccn1)Oc2ccc(c(c2)F)NC(=O)Nc3ccc(c(c3)C(F)(F)F)Cl,FNHKPVJBJVTLMP-UHFFFAOYSA-N
210,Icotinib,,4.0,Zhejiang Beta Pharma,,,,0,391.2,3.2,74.7,7,1,2,"Icotinib hydrochloride is a novel epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitor, exhibits encouraging efficacy and tolerability in  patients with advanced non-small-cell lung cancer (NSCLC) who failed previous chemotherapy.",['EGFR'],['Tyr'],2011,,,['BPI-2009H'],N,,C#Cc1cccc(c1)Nc2c3cc4c(cc3ncn2)OCCOCCOCCO4,QQLKULDARVNMAL-UHFFFAOYSA-N
211,Idelalisib,['Zydelig'],4.0,Gilead Sciences,40L,['4xe0'],1.0,0,415.2,3.8,101.4,7,2,5,"Idelalisib is indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed sma ll lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination with rituximab in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities, while in the treatment of FL and SLL it is intended to be used in patients who have received at least two prior systemic therapies.",['PIK3CD'],['Atypical'],2014,US-6800620-B2,Single Stereoisomer,"['Zydelig', 'GS-1101', 'GS-11CAL-101', 'Idelalisib', 'CAL-101']",Y,,CC[C@@H](c1nc2cccc(c2c(=O)n1c3ccccc3)F)Nc4c5c([nH]cn5)ncn4,IFSDAJWBUCMOAH-HNNXBMFYSA-N
212,Imatinib,['Gleevec'],4.0,Novartis,STI,"['1iep', '1opj', '1t46', '1xbb', '2hyy', '2oiq', '2pl0', '3fw1', '3gvu', '3hec', '3k5v', '3ms9', '3mss', '3oez', '3pyy', '4bkj', '4csv', '4r7i', '5mqt', '6hd4', '6hd6', '6npe', '6npu', '6npv']",2.0,0,493.3,4.6,86.3,7,2,7,"For the treatment of Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML), Ph+ acute lymphoblastic leukaemia, myelodysplastic/myeloprol iferative diseases, aggressive systemic mastocytosis, hypereosinophilic syndrome and/or chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans, and malignant gastrointestinal stromal tumors (GIST).","['KIT', 'RET', 'NTRK1', 'CSF1R', 'PDGFRA', 'DDR1', 'ABL1', 'PDGFRB']",['Tyr'],2001,US-6894051-B1,Achiral Molecule,"['Gleevec', 'Imatinib', 'STI-571']",Y,226,Cc1ccc(cc1Nc2nccc(n2)c3cccnc3)NC(=O)c4ccc(cc4)CN5CCN(CC5)C,KTUFNOKKBVMGRW-UHFFFAOYSA-N
213,Ponatinib,['Iclusig'],4.0,Ariad Pharmaceuticals,0LI,"['3ik3', '3oxz', '3zos', '4c8b', '4qrc', '4tyj', '4u0i', '4uxq', '4v01', '4v04', '6eg9']",2.0,1,532.2,4.5,65.8,6,1,4,"Ponatinib is indicated for the treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) that i s resistant or intolerant to prior tyrosine kinase inhibitor therapy or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy.","['ABL1', 'BCR', 'KIT', 'RET', 'TEK', 'FLT3', 'FGFR1', 'FGFR2', 'FGFR3', 'FGFR4', 'LCK', 'SRC', 'LYN', 'KDR', 'PDGFRA']","['Atypical', 'Tyr']",2012,US-8114874-B2,Achiral Molecule,"['Iclusig', 'AP-24534', 'Ponatinib']",Y,,Cc1ccc(cc1C#Cc2cnc3n2nccc3)C(=O)Nc4ccc(c(c4)C(F)(F)F)CN5CCN(CC5)C,PHXJVRSECIGDHY-UHFFFAOYSA-N
214,Lapatinib,['Tykerb'],4.0,GlaxoSmithKline,FMM,"['1xkk', '3bbt']",1.5,2,580.1,6.1,106.4,8,2,11,"Indicated in combination with capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress the human  epidermal receptor type 2 (HER2) protein and who have received prior therapy including an anthracycline, a taxane, and trastuzuma.","['EGFR', 'ERBB2']",['Tyr'],2007,US-6391874-B1,Achiral Molecule,"['Tyverb', 'GW-2016', 'GW-572016', 'Lapatinib']",Y,,CS(=O)(=O)CCNCc1ccc(o1)c2ccc3c(c2)c(ncn3)Nc4ccc(c(c4)Cl)OCc5cccc(c5)F,BCFGMOOMADDAQU-UHFFFAOYSA-N
215,Ribociclib,['Kisqali'],4.0,Novartis,6ZZ,['5l2t'],1.0,0,434.3,2.8,91.2,8,2,5,"Kisqali (ribociclib) is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two pro teins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced precision may play a role in ensuring that cancer cells do not continue to replicate uncontrollably.","['CDK4', 'CDK6']",['CMGC'],2017,US-8324225-B2,Achiral Molecule,"['Ribociclib', 'LEE-011', 'NVP-LEE011']",Y,,CN(C)C(=O)c1cc2cnc(nc2n1C3CCCC3)Nc4ccc(cn4)N5CCNCC5,RHXHGRAEPCAFML-UHFFFAOYSA-N
216,Apatinib,,4.0,Bukwang Pharmaceutical,,,,1,397.2,5.1,90.7,5,2,5,"Apatinib mesylate is an orally bioavailable, small-molecule receptor tyrosine kinase inhibitor with potential antiangiogenic and antineoplastic activi ties. The free-base form is also known as Rivoceranib. Apatinib selectively binds to and inhibits vascular endothelial growth factor receptor 2, which may inhibit VEGF-stimulated endothelial cell migration and proliferation and decrease tumor microvessel density. In addition, this agent mildly inhibits c-Kit and c-SRC tyrosine kinases.",['KDR'],['Tyr'],2014,,,"['NO.', 'STUDY', 'DRUG', '5-FLUOROURACIL', 'VP-16', 'ALBUMIN', 'PACLITAXEL', 'AITAN', 'DOCETAXEL', 'EGAFUR', 'EMOZOLOMIDE（TMZ）', 'PLATINU', 'NAVELBINE+AITAN', 'PEMETREXED', 'H20140103', 'S1', 'ARGET', 'THERAPY', 'SPA', 'YN968D1', 'CARBOPLATIN', 'ARM', 'A', 'PACLITAXOL', 'XELOX', 'APATINIB', 'GROUP', 'S-1', 'ATAN', 'AI', 'TAN', 'APATINIB', 'REATMENT', 'GROUP', 'CAPECITABINE', 'YEW', 'APATINIB', 'MESYLATE', 'ESYLATE', 'APATINIB', 'APATINIB', 'TABLETS', 'OXALIPLATIN', 'YN968D1,(AITAN®']",N,,N#CC1(CCCC1)c1ccc(cc1)NC(=O)c1cccnc1Nc1cnccc1C,MGZNERAVOCFMCU-UHFFFAOYSA-N
217,Midostaurin,['Rydapt'],4.0,Novartis Pharmaceuticals Corp,2K2,['4nct'],,2,570.2,5.9,77.7,6,1,3,"On april 28 , 2017, the FDA approved midostaurin to  treat acute myeloid leukemia",,,2017,US-7973031-B2,Single Stereoisomer,"['Rydapt', 'Midostaurin', 'NVP-PKC412', 'PKC-412', 'CGP-41251']",Y,235-260,C[C@@]12[C@@H]([C@@H](C[C@@H](O1)n3c4ccccc4c5c3c6n2c7ccccc7c6c8c5C(=O)NC8)N(C)C(=O)c9ccccc9)OC,BMGQWWVMWDBQGC-IIFHNQTCSA-N
